Document:

Exhibit 10.10

 

Execution Version

 

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.

 

 

SEPARATION AND DISTRIBUTION AGREEMENT

 

dated as of February 9, 2014

 

entered into by and among

 

IKARIA, INC.,

 

BELLEROPHON THERAPEUTICS LLC

 

and

 

IKARIA ACQUISITION INC.

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    
	
ARTICLE 1 DEFINITIONS
    	
3
    
	
ARTICLE 2 ASSET TRANSFERS
    	
15
    
	
 
    	
 
    
	
Section 2.1
    	
Transfer of Assets, Assumption of Liabilities
    	
15
    
	
Section 2.2
    	
Further Assurances
    	
16
    
	
Section 2.3
    	
Transfers Not Effected Prior to Distribution
    	
16
    
	
Section 2.4
    	
Bank Accounts
    	
17
    
	
Section 2.5
    	
Novation of R&DCo Liabilities
    	
17
    
	
Section 2.6
    	
Novation of Ikaria Liabilities
    	
18
    
	
 
    	
 
    	
 
    
	
ARTICLE 3 THE DISTRIBUTION
    	
18
    
	
 
    	
 
    
	
Section 3.1
    	
The Distribution
    	
18
    
	
Section 3.2
    	
Actions Prior to the Distribution
    	
20
    
	
Section 3.3
    	
Certain Stockholder Matters
    	
20
    
	
 
    	
 
    	
 
    
	
ARTICLE 4 ACCESS TO INFORMATION; FINANCIAL   STATEMENTS
    	
21
    
	
 
    	
 
    
	
Section 4.1
    	
Restrictions on Disclosure of Information
    	
21
    
	
Section 4.2
    	
Protective Arrangements
    	
22
    
	
Section 4.3
    	
Provision of Corporate Records; Access to Information
    	
22
    
	
Section 4.4
    	
Record Retention
    	
24
    
	
Section 4.5
    	
Production of Witnesses
    	
24
    
	
Section 4.6
    	
Financial Statements and Accounting
    	
25
    
	
Section 4.7
    	
Reimbursement
    	
25
    
	
Section 4.8
    	
Other Agreements Regarding Access to Information
    	
26
    
	
Section 4.9
    	
Limitations of Liability
    	
26
    
	
 
    	
 
    	
 
    
	
ARTICLE 5 ADDITIONAL COVENANTS AND OTHER MATTERS
    	
26
    
	
 
    	
 
    
	
Section 5.1
    	
Further Assurances
    	
26
    
	
Section 5.2
    	
Performance
    	
27
    
	
Section 5.3
    	
[Intentionally Omitted.]
    	
27
    
	
Section 5.4
    	
Insurance Matters
    	
27
    
	
Section 5.5
    	
Signs; Use of Names
    	
28
    
	
Section 5.6
    	
Indemnification of R&DCo Officers and Directors
    	
28
    
	
 
    	
 
    	
 
    
	
ARTICLE 6 INDEMNIFICATION; MUTUAL RELEASE
    	
28
    
	
 
    	
 
    
	
Section 6.1
    	
Indemnification by R&DCo Group
    	
28
    
	
Section 6.2
    	
Indemnification by Ikaria Group
    	
29
    
	
Section 6.3
    	
Claim Procedure
    	
29
    
	
Section 6.4
    	
Survival; Limitations
    	
31
    
	
Section 6.5
    	
Non-Recourse
    	
33
    
	
 
    	
 
    	
 
    
	
ARTICLE 7 DISPUTE RESOLUTION
    	
33
    

 

i

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    
	
Section 7.1
    	
Disputes
    	
33
    
	
Section 7.2
    	
Escalation; Mediation
    	
34
    
	
Section 7.3
    	
Court Actions
    	
34
    
	
 
    	
 
    	
 
    
	
ARTICLE 8 MISCELLANEOUS
    	
34
    
	
 
    	
 
    
	
Section 8.1
    	
Governing Law
    	
34
    
	
Section 8.2
    	
Jurisdiction
    	
35
    
	
Section 8.3
    	
Notices
    	
35
    
	
Section 8.4
    	
Binding Effect and Assignment
    	
36
    
	
Section 8.5
    	
Severability
    	
36
    
	
Section 8.6
    	
Specific Performance
    	
37
    
	
Section 8.7
    	
Entire Agreement
    	
37
    
	
Section 8.8
    	
No Third-Party Beneficiaries
    	
37
    
	
Section 8.9
    	
Counterparts and Signature
    	
37
    
	
Section 8.10
    	
Expenses
    	
37
    
	
Section 8.11
    	
Amendment
    	
38
    
	
Section 8.12
    	
Waiver
    	
38
    
	
Section 8.13
    	
Authority; R&DCo Assets
    	
38
    
	
Section 8.14
    	
Construction of Agreement
    	
38
    
	
Section 8.15
    	
Termination
    	
40
    
	
Section 8.16
    	
Insurance
    	
40
    
	
 
    	
 
    
	
 
    	
 
    
	
Schedules:
    	
 
    
	
 
    	
 
    
	
1.1(a)
    	
Ikaria Names
    
	
1.1(b)
    	
R&DCo   Intellectual Property
    
	
6.1(c)
    	
Indemnification   Matters
    
	
8.13(a)
    	
R&DCo Assets   Used in or Necessary for Ikaria Business
    
	
8.13(b)
    	
Required   Consents
    
	
 
    	
 
    
	
Exhibits
    	
 
    
	
 
    
	
Exhibit A
    	
-
    	
Form of   Device Clinical Supply Agreement
    
	
Exhibit B
    	
-
    	
Form of   Drug Clinical Supply Agreement
    
	
Exhibit C
    	
-
    	
Form of   Employee Matters Agreement
    
	
Exhibit D
    	
-
    	
Form of   R&D Cross License Agreement
    
	
Exhibit E
    	
-
    	
Form of   Transition Services Agreement
    

 

ii

 

SEPARATION AND DISTRIBUTION AGREEMENT

 

This SEPARATION AND DISTRIBUTION AGREEMENT, dated as of February 9, 2014 (this “Agreement”), is entered into by and among Ikaria, Inc., a Delaware corporation (“Ikaria”), Ikaria Acquisition Inc., a Delaware corporation (together with its successor, Ikaria Acquisition LLC, a Delaware limited liability company “AcquisitionCo”), and Bellerophon Therapeutics LLC, a Delaware limited liability company (“R&DCo”).  Each of Ikaria and R&DCo are sometimes referred to herein as a “Party,” and Ikaria and R&DCo are sometimes referred to herein collectively as the “Parties.”  Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Article 1 of this Agreement.

 

RECITALS

 

WHEREAS, Ikaria is a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the significant unmet medical needs of critically ill patients;

 

WHEREAS, the Board of Directors of Ikaria (the “Ikaria Board”) has determined that it is appropriate, desirable and in the best interests of Ikaria and its stockholders to separate Ikaria into two independent companies, one for each of: (a) the Ikaria Business, which shall continue to be owned and conducted, directly or indirectly, in addition to any other line of business it may conduct, by Ikaria, and (b) the R&DCo Business, which shall be owned and conducted, directly or indirectly, by R&DCo (such separation, the “Separation”);

 

WHEREAS, (a) the applicable Ikaria Group Members have transferred, or will transfer, all of their right, title and interest in and to the R&DCo Assets to the applicable R&DCo Group Members; (b) the applicable R&DCo Group Members have transferred, or will transfer, all of their right, title and interest in and to the Ikaria Assets to the applicable Ikaria Group Members; (c) the applicable Ikaria Group Members have assumed, or will assume, the Ikaria Liabilities; and (d) the applicable R&DCo Group Members have assumed, or will assume, the R&DCo Liabilities, in each case as more fully described in this Agreement and the Ancillary Documents;

 

WHEREAS, INO Therapeutics LLC, a Delaware limited liability company (“INO Therapeutics”), is entering into the R&D Cross-License Agreement with Bellerophon Pulse Technologies LLC (formerly known as Ikaria Pulse Technologies LLC), a Delaware limited liability company (“Pulse Technologies”), pursuant to which the parties thereto have granted to one another the rights and licenses set forth therein;

 

WHEREAS, AcquisitionCo is a direct Subsidiary of Ikaria, and INO Therapeutics is a direct Subsidiary of AcquisitionCo;

 

WHEREAS, for purposes of completing the Separation, (a) R&DCo has been formed as a direct Subsidiary of AcquisitionCo; (b) Pulse Technologies was formed initially as a direct Subsidiary of INO Therapeutics; (c) INO Therapeutics distributed to AcquisitionCo, by means of a special dividend, 100% of the outstanding membership interests of Pulse Technologies; (d) Ikaria Development Subsidiary One LLC, a Delaware limited liability company and a direct Subsidiary of AcquisitionCo, was initially renamed Ikaria BCM LLC and has been subsequently 

 

 

renamed Bellerophon BCM LLC (“Bellerophon BCM”); (e) AcquisitionCo contributed 100% of the membership interests of each of Pulse Technologies and Bellerophon BCM to R&DCo; and (f) R&DCo formed Bellerophon Services, Inc., a Delaware corporation, as its wholly owned subsidiary (“ServicesCo” and, together with Pulse Technologies and Bellerophon BCM, the “R&DCo Subsidiaries”);

 

WHEREAS, on or prior to the date hereof AcquisitionCo will have distributed to Ikaria, by means of a special dividend, 1% of the outstanding R&DCo Voting Units (the “Initial Distribution”);

 

WHEREAS, following the Initial Distribution but prior to the Merger Closing, all outstanding shares of Ikaria’s preferred stock, par value $0.01 per share, and non-voting common stock, par value $0.01 per share, will convert into shares of Ikaria’s voting common stock, par value $0.01 per share, pursuant to the terms of an amendment to be filed to Ikaria’s Restated Certificate of Incorporation (the “Stock Conversion”);

 

WHEREAS, following the Stock Conversion, Ikaria will distribute to holders of shares of Ikaria Capital Stock, by means of a special dividend, the R&DCo Voting Units received by Ikaria in the Initial Distribution, as more fully described in this Agreement and the Ancillary Documents (such distribution, the “1% Distribution”);

 

WHEREAS, immediately following the 1% Distribution, AcquisitionCo will convert from a Delaware corporation into a Delaware limited liability company (the “LLC Conversion”);

 

WHEREAS, following the LLC Conversion but prior to the Merger Closing, (a) AcquisitionCo will distribute to Ikaria, by means of a special dividend, the remaining R&DCo Voting Units held by AcquisitionCo and (b) immediately thereafter, Ikaria shall distribute to holders of shares of Ikaria Capital Stock, by means of a special dividend, such R&DCo Voting Units, as more fully described in this Agreement and the Ancillary Documents (the “99% Distribution” and, together with the 1% Distribution, the “Distribution”);

 

WHEREAS, this Agreement is being entered into in connection with and prior to the consummation (the “Merger Closing”) of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of December 24, 2013 (as amended, the “Merger Agreement”), by and between Ikaria, Compound Holdings I, LLC, a Delaware limited liability company (“Purchaser Parent”), Compound Holdings II, Inc., a Delaware corporation and wholly owned Subsidiary of Purchaser Parent (“Purchaser”), Compound Merger Sub I, Inc., a Delaware corporation and wholly owned Subsidiary of Purchaser Parent, Compound Merger Sub II, Inc., a Delaware corporation and wholly owned Subsidiary of Purchaser, and New Mountain Partners II, L.P., a Delaware limited partnership, solely in its capacity as the stockholder representative; and

 

WHEREAS, it is appropriate and desirable to set forth certain transactions required to effect the Separation, the Distribution and certain other agreements that will govern certain matters relating to the Separation, the Distribution and the relationship of Ikaria, R&DCo and their respective Subsidiaries following the Separation and the Distribution.

 

2

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth below, and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties hereby agree as follows:

 

ARTICLE 1
 DEFINITIONS

 

The following terms, as used in this Agreement, have the following meanings:

 

“1% Distribution” has the meaning set forth in the Recitals to this Agreement.

 

“99% Distribution” has the meaning set forth in the Recitals to this Agreement.

 

“access” has the meaning set forth in Section 4.3(b).

 

“Accredited Investor” has the meaning ascribed thereto in Rule 501 under the Securities Act.

 

“AcquisitionCo” has the meaning set forth in the Recitals to this Agreement.

 

“Action” means any action, claim, demand, suit, arbitration, mediation, inquiry, audit, hearing, proceeding or investigation by or before any Governmental Authority.

 

“Affiliate” of any Person means a Person that controls, is controlled by, or is under common control with such Person. It is expressly agreed that, from and after the Distribution, solely for purposes of this Agreement (a) no member of the R&DCo Group shall be deemed to be an Affiliate of any member of the Ikaria Group and (b) no member of the Ikaria Group shall be deemed to be an Affiliate of any member of the R&DCo Group.

 

“Agreement” has the meaning set forth in the preamble to this Agreement.

 

“Ancillary Documents” means each of the Transition Services Agreement, the R&D Cross-License Agreement, the Manufacturing and Supply Agreements, the Employee Matters Agreement and the Non-Competition Agreements, including any exhibits, schedules, attachments, tables or other appendices thereto.

 

“Assets” means assets, properties, claims and rights (including goodwill), wherever located (including in the possession of vendors or other third parties or elsewhere), of every kind, character and description, whether real, personal or mixed, tangible, intangible or contingent, in each case whether or not recorded or reflected or required to be recorded or reflected on the books and records or financial statements of any Person.

 

“BCM” (Bioabsorbable Cardiac Matrix) means a polymer comprised of Sodium Alginate and Calcium D-Gluconate (including that designated by Ikaria as “IK-5001” and by BioLineRx 

 

3

 

as “BL-1040”), or any back-ups or second-generation or other future polymers or polymer combinations thereof, for any and all uses, including uses for the prevention of left ventricular remodeling after acute myocardial infarction or other indication.

 

“BCM Business” means the use of a polymer comprised of Sodium Alginate and Calcium D-Gluconate currently referred to as Bellerophon BCM LLC’s Bioabsorbable Cardiac Matrix (BCM) asset (or any back-ups or second-generation or other future polymers or polymer combinations thereof) in the management of acute myocardial infarction, or the prevention of left ventricular remodeling and the prevention of the progression to heart failure following acute myocardial infarction.

 

“Bellerophon BCM” has the meaning set forth in the Recitals to this Agreement.

 

“Business Day” means a day other than a Saturday, a Sunday or a day on which banking institutions located in New York, New York are authorized or obligated by Law to close.

 

“Cash and Cash Equivalents” has the meaning set forth in the definition of “R&DCo Assets” set forth herein.

 

“Claim Notice” has the meaning set forth in Section 6.3(a).

 

“Claimed Amount” has the meaning set forth in Section 6.3(a).

 

“Consents” means any consents, waivers or approvals from, or notification requirements to, any third parties.

 

“Contracts” means any contract, agreement, lease, license, sales order, purchase order, instrument or other commitment that is binding on any Person or any part of its property under applicable Law.

 

“control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through ownership of voting securities or other interests, by contract or otherwise.

 

“Control Assessments and Audit” has the meaning set forth in Section 4.6(b).

 

“Controlling Party” has the meaning set forth in Section 6.3(d)(ii).

 

“COPD” means pulmonary hypertension secondary to chronic obstructive pulmonary disease.

 

“Copyright” has the meaning set forth in the definition of “Intellectual Property” contained herein.

 

“Damages” means all losses, claims, demands, damages, Liabilities, Taxes, judgments, dues, penalties, assessments, fines (civil, criminal or administrative), costs, liens, forfeitures, settlements, fees or expenses (including reasonable attorneys’ fees and expenses and any other 

 

4

 

expenses reasonably incurred in connection with investigating, prosecuting or defending a claim or Action), of any nature or kind, whether or not the same would properly be reflected on a balance sheet.

 

“Device Clinical Supply Agreement” means that certain Device Clinical Supply Agreement to be entered into by and between INO Therapeutics and Pulse Technologies on or prior to the Distribution Date, in the form attached hereto as Exhibit A.

 

“Distribution” has the meaning set forth in the Recitals to this Agreement.

 

“Distribution Date” means the date on which the 99% Distribution occurs.

 

“Drug Clinical Supply Agreement” means that certain Drug Clinical Supply Agreement to be entered into by and between INO Therapeutics and Pulse Technologies on or prior to the Distribution Date, in the form attached hereto as Exhibit B.

 

“Employee Matters Agreement” means that certain Employee Matters Agreement to be entered into by and between Ikaria and R&DCo on or prior to the Distribution Date, in the form attached hereto as Exhibit C.

 

“Environmental Law” means any Law or any Permit relating to health, safety, pollution or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata) or to Releases or threatened Releases of any Hazardous Material, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of any Hazardous Material, including the Comprehensive Environmental Response, Compensation and Liability Act, the Superfund Amendments and Reauthorization Act and the Resource Conservation and Recovery Act and comparable provisions in state, local, foreign or international Law.

 

“Environmental Liabilities” means all Liabilities (including all removal, remediation, cleanup or monitoring costs, investigatory costs, response costs, natural resources damages, property damages, personal injury damages, judgment or other determination of Liability and indemnity, contribution or similar obligations and all costs and expenses, interest, fines, penalties or other monetary sanctions in connection therewith) relating to, arising out of or resulting from any (a) actual or alleged (i) compliance or noncompliance with any Environmental Law, (ii) generation, use, storage, manufacture, processing, handling, possession, management, treatment, transportation, distribution, emission, discharge or disposal of any Hazardous Material, or (iii) presence, Release or threatened Release of, or exposure to, any Hazardous Material (including any exposure of any current or former Employee (as defined in the Employee Matters Agreement) or any individual who is, or was, an independent contractor, temporary employee, temporary service worker, consultant, freelancer, agency employee, on-call worker, incidental worker, or non-payroll worker for any Ikaria Group Member or R&DCo Group Member, as the case may be, to Hazardous Materials, except for claims that arise under, or are covered or barred by, workers’ compensation laws and/or workers’ compensation, disability or other insurance providing medical care and/or compensation to injured workers) or (b) Contract pursuant to which Liability is assumed or imposed with respect to any of the foregoing.

 

5

 

“Escalation Notice” has the meaning set forth in Section 7.2(a).

 

“First Party” has the meaning set forth in Section 4.6(c).

 

“First Party’s Auditors” has the meaning set forth in Section 4.6(c).

 

“GAAP” means U.S. generally accepted accounting principles, consistently applied.

 

“Governmental Authority” means any federal, state, local or foreign governmental or quasi-governmental entity or municipality or subdivision thereof or any authority, department, commission, board, bureau, agency, court, tribunal or instrumentality, or any applicable securities exchange or self-regulatory organization.

 

“Group” means either the Ikaria Group or the R&DCo Group, as the context requires.

 

“Group Member” means either an Ikaria Group Member or an R&DCo Group Member, as the context requires.

 

“Hazardous Material” means (a) any petroleum or petroleum products, radioactive materials, toxic mold, radon, asbestos or asbestos-containing materials in any form, lead-based paint, urea formaldehyde foam insulation, or polychlorinated biphenyls (PCBs); and (b) any chemicals, materials, substances, compounds, mixtures, products or byproducts, biological agents, living or genetically modified materials, pollutants, contaminants or wastes that are now or hereafter become defined or characterized as or included in the definition of “hazardous substances,” “hazardous wastes,” “hazardous materials,” “extremely hazardous wastes,” “restricted hazardous wastes,” “special waste,” “toxic substances,” “pollutants,” “contaminants,” “toxic,” “dangerous,” “corrosive,” “flammable,” “reactive,” “radioactive,” or words of similar import, under any Environmental Law.

 

“Ikaria” has the meaning set forth in the preamble to this Agreement.

 

“Ikaria Assets” means:

 

(a)           the Ikaria Names and all other Intellectual Property of Ikaria and its Subsidiaries;

 

(b)           any and all Assets that are contemplated by this Agreement or any Ancillary Document (including any schedule or exhibit hereto or thereto) as Assets to be retained by an Ikaria Group Member;

 

(c)           the capital stock and other equity interests of each of Ikaria’s Subsidiaries other than R&DCo and the R&DCo Subsidiaries;

 

(d)           all Contracts to which Ikaria or any of its Subsidiaries is a party or by which they or any of their respective Assets are bound and any rights or claims (whether accrued or contingent) of Ikaria or any of its Subsidiaries arising thereunder, other than this Agreement and the Ancillary Documents;

 

6

 

(e)           the Ikaria Books and Records;

 

(f)            all Tax credits, receivables, and loss carryforwards from Tax authorities of Ikaria and its Subsidiaries; and

 

(g)           all other Assets of Ikaria and its Subsidiaries (treating for this purpose the R&DCo Group as Subsidiaries of Ikaria prior to the Distribution) that are not R&DCo Assets.

 

“Ikaria Board” has the meaning set forth in the Recitals to this Agreement.

 

“Ikaria Books and Records” means originals or true and complete copies thereof, including electronic copies (if available), of (a) minute books, corporate charters and bylaws or comparable constitutive documents, records of share issuances and related corporate records, of the Ikaria Group; (b) all books and records relating to (i) Ikaria Employees, (ii) the purchase of materials, supplies and services for the Ikaria Business, (iii) dealings with customers of the Ikaria Business and (iv) dealings with licensors to the Ikaria Business; and (c) all files relating to any Action the Liability with respect to which is an Ikaria Liability. Notwithstanding the foregoing, “Ikaria Books and Records” shall not include (A) any Tax Returns that relate solely to any R&DCo Group Member or (B) the R&DCo Books and Records.

 

“Ikaria Business” means the businesses or operations of the Ikaria Group other than the R&DCo Business.

 

“Ikaria Capital Stock” means any of the outstanding shares of capital stock of Ikaria, including shares of its (a) common stock, par value $0.01 per share, and (b) preferred stock, par value $0.01 per share, regardless of (i) whether such shares are designated “voting” or “non-voting” and (ii) which class such shares have been designated, in each case, pursuant to Ikaria’s Restated Certificate of Incorporation, as amended.

 

“Ikaria Employee” has the meaning set forth in the Employee Matters Agreement.

 

“Ikaria Group” means Ikaria and each other Person that Ikaria now or hereafter controls (other than R&DCo or any R&DCo Group Member).

 

“Ikaria Group Member” means any Person now or hereafter included in the Ikaria Group.

 

“Ikaria Indemnified Parties” has the meaning set forth in Section 6.1.

 

“Ikaria Liabilities” means:

 

(a)           any and all Liabilities that are expressly contemplated by this Agreement or any Ancillary Document (or any other schedule hereto or thereto) as Liabilities to be retained or assumed by an Ikaria Group Member, and all agreements and obligations of any Ikaria Group Member under this Agreement or any of the Ancillary Documents;

 

(b)           any and all Liabilities relating to, arising out of or resulting from any Ikaria Assets;

 

7

 

(c)           any and all Environmental Liabilities relating to, arising out of or resulting from:

 

(i)            researching, developing, manufacturing, finishing, marketing, distributing, leasing, selling or other operations associated with the Ikaria Business and the Ikaria Assets to the extent conducted by Ikaria and its Subsidiaries, at any time at or prior to the date hereof in any such case whether occurring or arising before, on or after the date hereof; or

 

(ii)           any real property that is an Ikaria Asset, whether occurring or arising before, on or after the date hereof.

 

(d)           any and all Liabilities relating to, arising out of or resulting from any Indebtedness of any Ikaria Group Member (whether incurred prior to, or after the date hereof);

 

(e)           any and all Liabilities of the Ikaria Group for Taxes that are imposed on the Ikaria Group (A) on or before the Distribution with respect to the operations of the R&DCo Group prior to the Distribution, and (B) with respect to the operations of the Ikaria Group, whether or not such Taxes are attributable to R&DCo Assets, including any Taxes incurred as the result of the Distribution; and

 

(f)            any and all other Liabilities of Ikaria and its Subsidiaries that are not R&DCo Liabilities;

 

provided that, notwithstanding anything herein to the contrary, Ikaria Liabilities shall not include any R&DCo Liabilities.

 

“Ikaria Names” means the trade names specified on Schedule 1.1(a) (and any derivatives of any such trade name) and associated logos or Trademarks.

 

“Ikaria Stock Option” has the meaning set forth in the Employee Matters Agreement.

 

“Ikaria RSU” has the meaning set forth in the Employee Matters Agreement.

 

“Indebtedness” of any Person means (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property or assets purchased by such Person, (e) all obligations of such Person issued or assumed as the deferred purchase price of property or services, (f) all indebtedness of others secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, or other encumbrance on property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed, (g) all guarantees by such Person of indebtedness of others, (h) all capital lease obligations of such Person and (i) all securities or other similar instruments convertible or exchangeable into any of the foregoing, but excluding daily cash overdrafts associated with routine cash operations.

 

“Indemnified Party” has the meaning set forth in Section 6.3(a).

 

8

 

“Indemnifying Party” has the meaning set forth in Section 6.3(a).

 

“Information” means information, whether or not patentable or copyrightable, in written, oral, electronic or other tangible or intangible form, stored in any medium, including studies, reports, records, books, contracts, instruments, surveys, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints, diagrams, models, prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes, computer programs or other software, marketing plans, customer names, communications by or to attorneys (including attorney-client privileged communications), memos and other materials prepared by attorneys or under their direction (including attorney work product), and other technical, financial, employee or business information or data.

 

“Initial Distribution” has the meaning set forth in the Recitals to this Agreement.

 

“INO Therapeutics” has the meaning set forth in the Recitals to this Agreement.

 

“Intellectual Property” means all intellectual property throughout the world, including all U.S. and foreign (a) patents, invention disclosures, and all related continuations, continuations-in-part, divisionals, provisionals, renewals, reissues, re-examinations, additions, extensions (including all supplementary protection certificates), and all applications and registrations therefor (“Patent Rights”), (b) trademarks, service marks, names, corporate names, trade names, domain names, logos, slogans, trade dress, design rights, and other similar designations of source or origin and all applications and registrations therefor, together with the goodwill symbolized by any of the foregoing (“Trademarks”), (c) copyrights and copyrightable subject matter and all applications and registrations therefor (“Copyrights”), and (d) any and all trade secrets, confidential data and technical information, including practices, techniques, methods, processes, inventions, developments, specifications, formulations, manufacturing processes, structures, chemical or biological manufacturing control data, analytical and quality control information and procedures, pharmacological, toxicological and clinical test data and results, stability data, studies and procedures and regulatory information (“Know-How”).

 

“Internal Reorganization Contracts” means (i) that certain Contribution Agreement, dated as of October 17, 2013, by and between INO Therapeutics and Pulse Technologies; (ii) that certain Contribution Agreement, dated as of October 17, 2013, by and between AcquisitionCo and R&DCo; (iii) that certain Contribution Agreement, dated as of October 17, 2013, by and between AcquisitionCo and R&DCo; (iv) that certain Assignment and Assumption Agreement, dated as of October 17, 2013, by and between Ikaria and Bellerophon BCM; (v) that certain Assignment and Assumption Agreement, dated as of October 17, 2013, by and between Ikaria Therapeutics LLC and Bellerophon BCM; (vi) that certain Assignment and Assumption Agreement, dated as of October 17, 2013, by and between INO Therapeutics and Bellerophon BCM; and (vii) that certain Contribution Agreement, dated as of February 7, 2014, by and between Ikaria, INO Therapeutics and ServicesCo.

 

“IPF” shall mean idiopathic pulmonary fibrosis.

 

“Know-How” has the meaning set forth in the definition of “Intellectual Property”.

 

9

 

“Law” means each applicable law, order, judgment, rule, code, statute, regulation, requirement, variance, decree, writ, injunction, award, ruling or ordinance of any Governmental Authority, including the common law.

 

“Liabilities” means debts, liabilities, guarantees, assurances, commitments and obligations of any nature or description, whether fixed, contingent or absolute, asserted or unasserted, matured or unmatured, liquidated or unliquidated, accrued or not accrued, known or unknown, due or to become due, whenever or however arising (including any of the foregoing arising out of (a) any Contract or tort based on negligence or strict liability or (b) any act or failure to act by any past or present Representative, whether or not such act or failure to act was within such Representative’s authority), and whether or not the same would be required by GAAP to be reflected in financial statements or disclosed in the notes thereto.

 

“Lien” means any mortgage, security interest, pledge, lien, charge, claim, option, right to acquire, voting or other restriction, right-of-way, covenant, condition, easement, encroachment, restriction on transfer or other encumbrance of any nature whatsoever.

 

“LLC Conversion” has the meaning set forth in the Recitals to this Agreement.

 

“Manufacturing and Supply Agreements” means the Drug Clinical Supply Agreement and the Device Clinical Supply Agreement.

 

“Merger Agreement” has the meaning set forth in the Recitals to this Agreement.

 

“Non-Competition Agreements” means, collectively, the Agreement Not To Compete entered into by and between AcquisitionCo and Bellerophon BCM on September 20, 2013; the Agreement Not To Compete entered into by and between AcquisitionCo and Pulse Technologies on October 18, 2013; the Agreement Not To Compete entered into by and between AcquisitionCo and R&DCo on October 18, 2013; and the Agreement Not To Compete entered into by and between AcquisitionCo and ServicesCo on February 7, 2014.

 

“Non-controlling Party” has the meaning set forth in Section 6.3(d)(ii).

 

“Non-Party Affiliates” has the meaning set forth in Section 6.5.

 

“Other Party’s Auditors” has the meaning set forth in Section 4.6(c).

 

“PAH” shall mean primary or idiopathic pulmonary arterial hypertension

 

“Party” has the meaning set forth in the preamble to this Agreement.

 

“Patent Rights” has the meaning set forth in the definition of “Intellectual Property” contained herein.

 

“Permit” means any license, permit, franchise, approval, consent, registration or authorization issued by any Governmental Authority.

 

10

 

“Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization or any Governmental Authority.

 

“Possessor” has the meaning set forth in Section 4.3(b).

 

“Post-Distribution Financing” means any public or private financing (or refinancing) undertaken by either Party or their respective Group Members, or a secondary offering of the securities of either Party or their respective Group Members by the stockholders of such Party or Group Members, following the Distribution Date, whether by means of a syndicated or unsyndicated commercial loan or a public or private offering of debt, equity or other securities.

 

“Pulse Technologies” has the meaning set forth in the Recitals to this Agreement.

 

“Purchaser Parent” has the meaning set forth in the Recitals to this Agreement.

 

“R&D Cross-License Agreement” means that certain Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement to be entered into by and between INO Therapeutics and Pulse Technologies on or prior to the Distribution Date, in the form attached hereto as Exhibit D.

 

“R&DCo” has the meaning set forth in the preamble to this Agreement.

 

“R&DCo Assets” means:

 

(a)           all Assets (i) that were transferred to R&DCo or its Subsidiaries pursuant to the Internal Reorganization Contracts and (ii) that are used solely and/or held for use solely in the BCM Business;

 

(b)           the Intellectual Property described on Schedule 1.1(b);

 

(c)           all R&DCo Books and Records;

 

(d)           all accounting and other legal and business books, records, ledgers and files and all personnel records, in each case, whether printed, electronic, contained on storage media or written, or in any other form, in each case only to the extent solely relating to the R&DCo Business;

 

(e)           all prepaid expenses, trade accounts and other accounts and notes receivable currently held by R&DCo that are not Ikaria Assets;

 

(f)            all cash or cash equivalents, certificates of deposit, banker’s acceptances and other investment securities of any form or maturity and all bank accounts, lock boxes and other deposit arrangements and all brokerage accounts currently held by R&DCo or its Subsidiaries, in each case net of outstanding or uncleared checks, drafts and wire transfers (collectively, “Cash and Cash Equivalents”); and

 

11

 

(g)           all accessories that interface or interoperate with, or support the use of, the Assets that were transferred by INO Therapeutics to Pulse Technologies pursuant to the Contribution Agreement, dated October 17, 2013, by and between INO Therapeutics and Pulse Technologies.

 

“R&DCo Books and Records” means originals or true and complete copies thereof, including electronic copies (if available), of (a) all minute books, certificates of formation, limited liability company agreements, and bylaws or comparable constitutive documents, records of membership interest, unit or share issuances and related records of each member of the R&DCo Group, (b) all books and records exclusively relating to (i) Transferred Employees, (ii) the purchase of materials, supplies and services for the R&DCo Business and (iii) dealings with licensors to the R&DCo Business and (c) all files relating exclusively to any Action the Liability with respect to which is an R&DCo Liability. Notwithstanding the foregoing, “R&DCo Books and Records” shall not include any Tax Returns that relate solely to the Ikaria Group.

 

“R&DCo Business” means the development, manufacture, commercialization, promotion, sale, import, export, servicing, repair, training, storage, distribution, transportation, licensing or other handling or disposition of nitric oxide, a device intended to deliver nitric oxide, or a service that delivers or supports the delivery of nitric oxide for or in connection with the outpatient, chronic treatment of patients who have COPD, IPF, or PAH, in each case even if initiation of therapy occurs in a hospital setting or such treatment occurs as part of episodic treatment or hospitalization of patients with COPD, IPF or PAH.  In addition, the term “R&DCo Business” shall also include the BCM Business.

 

“R&DCo Group” means R&DCo, the R&DCo Subsidiaries and each other Person that R&DCo controls.

 

“R&DCo Group Member” means any Person now or hereafter included in the R&DCo Group.

 

“R&DCo Indemnified Parties” has the meaning set forth in Section 6.2.

 

“R&DCo Liabilities” means:

 

(a)           any and all Liabilities that are expressly contemplated by this Agreement or any Ancillary Document (or any other schedules hereto or thereto) as Liabilities to be retained or assumed by any R&DCo Group Member, and all agreements, obligations and Liabilities of any R&DCo Group Member under this Agreement, or any of the Ancillary Documents;

 

(b)           any and all Liabilities relating to, arising out of or resulting from any R&DCo Assets;

 

(c)           any and all Liabilities relating to, arising out of or resulting from the conduct and operation of the R&DCo Business, at any time prior to, on or after the date hereof (including any such Liability relating to, arising out of or resulting from any act or failure to act by any Representative of any Ikaria Group Member (whether or not such act or failure to act is or was within such Representative’s authority)), in any such case whether occurring or arising before, on or after the date hereof;

 

12

 

(d)           any and all Environmental Liabilities relating to, arising out of or resulting from the R&DCo Business or any R&DCo Assets, in any such case whether occurring or arising before, on or after the date hereof;

 

(e)           any and all Liabilities that were assumed by R&DCo or its Subsidiaries pursuant to the Internal Reorganization Contracts;

 

(f)            any and all Liabilities relating to, resulting from or arising out of any Action to the extent relating to the R&DCo Group;

 

(g)           any and all Liabilities arising out of claims made by R&DCo’s directors, officers, employees, agents, Subsidiaries or Affiliates against any member of the Ikaria Group or the R&DCo Group to the extent relating to the R&DCo Business; and

 

(h)           any and all Liabilities of the R&DCo Group for Taxes that are imposed on the R&DCo Group with respect to the operations of the R&DCo Group after the Distribution.

 

“R&DCo LLC Agreement” means the Amended & Restated Limited Liability Company Agreement of Bellerophon Therapeutics LLC to be entered into on or about the date hereof (as amended, modified or supplemented from time to time).

 

“R&DCo Non-Voting Units” means the Units denominated as Non-Voting Units pursuant to the Amended and Restated Limited Liability Company Agreement of R&DCo.

 

“R&DCo Subsidiaries” has the meaning set forth in the Recitals to this Agreement.

 

“R&DCo Voting Units” means the Units denominated as Voting Units pursuant to the Amended and Restated Limited Liability Company Agreement of R&DCo.

 

“Record Date” means the close of business on the date to be determined by the Ikaria Board as the record date for determining the stockholders of Ikaria entitled to receive R&DCo Voting Units pursuant to the Distribution.

 

“Release” means any release, spill, emission, leaking, dumping, pumping, injection, pouring, deposit, disposal, discharge, dispersal, leaching or migration into the environment (including ambient air, surface water, groundwater, land surface or subsurface strata, soil and sediments).

 

“Representatives” means, with respect to any Person, any of such Person’s directors, officers, employees, agents, consultants, advisors, accountants, attorneys or other representatives.

 

“Requestor” has the meaning set forth in Section 4.3(b).

 

“Required Disclosure” means a disclosure of Information that (a) a Party or one of its Group Members determines is required pursuant to applicable Law (including the rules and regulations of the SEC or any national securities exchange, including as the same may apply to the registration of any securities in connection with a proposed Post-Distribution Financing), (b) 

 

13

 

is demanded or requested pursuant to any legal process or (c) is made in response to any demand or request by a Governmental Authority (including any such disclosure to the extent reasonably necessary to respond to any written request or official comment from a Governmental Authority, such as in connection with responding to (i) comment letters from SEC in connection with a Post-Distribution Financing or otherwise or (ii) requests for information from the U.S. Food and Drug Administration).

 

“Required R&DCo Financial Statements” shall mean (a) audited balance sheets of the R&DCo Business as of December 31, 2011 and December 31, 2012, and audited statements of operations, changes in invested equity (deficit) and cash flows for the R&DCo Business for each of the years ended December 31, 2011 and December 31, 2012 and for the period from August 26, 2009 (inception) to December 31, 2012, together with associated notes to those financial statements, in each case, prepared in accordance with GAAP, (b) an unaudited balance sheet as of September 30, 2013, and unaudited statements of operations, changes in invested equity (deficit) and cash flows for the R&DCo Business for each of the nine-month periods ended September 30, 2013 and 2012, together with associated notes to those unaudited financial statements, in each case, prepared in accordance with GAAP, and (c) reviews prepared by the R&DCo’s independent auditor in respect of such independent auditor’s performance of the procedures specified by the Public Company Accounting Oversight Board for a review of interim financial information as described in AU 722 with respect to the financial statements described in the foregoing clause (b).

 

“Restricted Information” has the meaning set forth in Section 4.3(b).

 

“Retention Period” has the meaning set forth in Section 4.4.

 

“SEC” means the United States Securities and Exchange Commission or any successor agency.

 

“Securities Act” means the Securities Act of 1933, as amended.

 

“Separation” has the meaning set forth in the Recitals to this Agreement.

 

“ServicesCo” has the meaning set forth in the Recitals to this Agreement.

 

“Stock Conversion” has the meaning set forth in the Recitals to this Agreement.

 

“Subsidiary” means with respect to any specified Person, any corporation or other legal entity of which such Person or any of its Subsidiaries controls or owns, directly or indirectly, more than 50% of the stock or other equity interest entitled to vote on the election of the members to the board of directors or similar governing body; provided, however, that unless the context otherwise requires, references to Subsidiaries of Ikaria shall not include R&DCo or any R&DCo Group Members.

 

“Tax” and “Taxes” means any and all taxes, charges, fees, duties, contributions, levies or other similar assessments or liabilities, including, without limitation, income, gross receipts, corporation, ad valorem, premium, value-added, net worth, capital stock, capital gains, 

 

14

 

documentary, recapture, alternative or add-on minimum, disability, registration, recording, excise, real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, employment, unemployment, insurance, social security, national insurance, business license, business organization, environmental, workers compensation, payroll, profits, severance, stamp, occupation, escheat, windfall profits, customs duties, franchise, estimated and other taxes of any kind whatsoever imposed by the United States of America or any state, local or foreign government, or any agency or political subdivision thereof, and any interest, fines, penalties, assessments or additions to tax imposed with respect to such items or any contest or dispute thereof.

 

“Tax Return” means any and all reports, returns (including information returns), declarations, or statements relating to Taxes, including any schedule or attachment thereto and any related or supporting workpapers or information with respect to any of the foregoing, including any amendment thereof filed with or submitted to any Governmental Entity in connection with the determination, assessment, collection or payment of Taxes or in connection with the administration, implementation or enforcement of or compliance with any legal requirement relating to any Tax, and including, for the avoidance of doubt, U.S. Department of the Treasury Form TD F 90-22.1.

 

“Third-Party Claim” has the meaning set forth in Section 6.3(d)(i).

 

“Trademark” has the meaning set forth in the definition of “Intellectual Property” contained herein.

 

“Transferred Employees” has the meaning set forth in the Employee Matters Agreement.

 

“Transition Services Agreement” means the Transition Services Agreement entered into by and between Ikaria and R&DCo, effective on or prior to the Distribution Date, to be in the form attached hereto as Exhibit E.

 

ARTICLE 2
 ASSET TRANSFERS

 

Section 2.1            Transfer of Assets, Assumption of Liabilities.

 

(a)           Except to the extent otherwise provided in this Agreement or any Ancillary Document and only to the extent not previously effectuated prior to the date hereof, Ikaria shall (and Ikaria shall cause each other Ikaria Group Member to) assign, transfer and convey to the applicable R&DCo Group Members, and R&DCo shall (and R&DCo shall cause each other R&DCo Group Member to) receive and accept from the Ikaria Group Members, all of the Ikaria Group Members’ right, title and interest in and to the R&DCo Assets (with the R&DCo Assets relating to BCM being transferred to Bellerophon BCM, the R&DCo Assets relating to the employment of the Transferred Employees being transferred to ServicesCo and all other R&DCo Assets being transferred to Pulse Technologies).  To the extent not previously effectuated, such assignments, transfers and conveyances shall be effective immediately prior to the Distribution, or at such other times as may be provided in each respective Ancillary 

 

15

 

Document and shall be subject to the terms and conditions of this Agreement and any applicable Ancillary Document.

 

(b)           Except to the extent otherwise provided in this Agreement or any Ancillary Document and only to the extent not previously effectuated prior to the date hereof, R&DCo shall (and R&DCo shall cause each other R&DCo Group Member to) assume and on a timely basis pay, perform, satisfy and discharge the R&DCo Liabilities in accordance with their respective terms (with Bellerophon BCM assuming the R&DCo Liabilities relating to BCM, ServicesCo assuming the R&DCo Liabilities relating to the Transferred Employees, and Pulse Technologies assuming all other R&DCo Liabilities).  To the extent not previously effectuated prior to the date hereof, such assumptions of R&DCo Liabilities and Ikaria Liabilities shall be effective immediately prior to the Distribution or at such other times as may be provided in each respective Ancillary Document and shall be subject to the terms and conditions of this Agreement and any applicable Ancillary Document.

 

(c)           For a period of seven years following the Distribution, if at any time or from time to time any Party (or Person in such Party’s respective Group) shall receive or otherwise possess any Asset or Liability, as applicable, that is allocated to any other Person pursuant to this Agreement or any Ancillary Document, such Party shall use its reasonable best efforts to promptly transfer, or cause to be transferred, such Asset or Liability, as applicable, to the Person so entitled thereto or responsible for the assumption thereof; provided that R&DCo shall only be permitted to make claims under this Section 2.1(c) with respect to Cash and Cash Equivalents until the date that is 45 days after the Effective Time (as defined in the Merger Agreement), and if no such claims are made within such period, R&DCo shall have no further rights under this Section 2.1(c) with respect to Cash and Cash Equivalents following such date.

 

Section 2.2            Further Assurances.  In furtherance of the transactions contemplated by Section 2.1, except to the extent otherwise provided in this Agreement or in any Ancillary Document, from and after the Distribution Date, the Parties shall execute and deliver, and they shall cause their respective Subsidiaries, as applicable, to execute and deliver: (i) to the extent not executed and delivered prior thereto, the Ancillary Documents; (ii) such bills of sale, membership interest or unit, powers, certificates of title, assignments of Contracts, subleases and other instruments of transfer, conveyance and assignment as, and to the extent, necessary or appropriate to evidence (A) the transfer, conveyance and assignment to the R&DCo Group Members of all of the Ikaria Group Members’ right, title and interest in and to the R&DCo Assets and (B) the transfer, conveyance and assignment to the Ikaria Group Members of all of the R&DCo Group Members’ right, title and interest in and to the Ikaria Assets; and (iii) such assumptions of Contracts and other instruments of assumption as, and to the extent, necessary or convenient to evidence the valid and effective assumption of (A) the R&DCo Liabilities by the R&DCo Group Members and (B) the Ikaria Liabilities by the Ikaria Group Members.

 

Section 2.3            Transfers Not Effected Prior to Distribution.  The Parties acknowledge and agree that some of the transfers of R&DCo Assets contemplated by Section 2.1(a) may not be effected prior to the Distribution due to the inability of the Parties to take certain other actions necessary to effect such transfers prior to such time.  To the extent any transfers of such R&DCo Assets contemplated by Section 2.1(a) have not been fully effected prior to the Distribution, each 

 

16

 

of Ikaria and R&DCo shall cooperate and use its respective reasonable best efforts (and shall cause each of its applicable Group Members to use its respective reasonable best efforts) to take any other actions necessary to effect such transfers of such R&DCo Assets as promptly as practicable following the Distribution.

 

Section 2.4            Bank Accounts.

 

(a)           It is intended that R&DCo and Ikaria will maintain separate bank accounts and separate cash management processes.

 

(b)           As between Ikaria and R&DCo (and the members of their respective Groups), all payments made and reimbursements received after the date hereof by either Party (or member of its Group) that relate to a business, Asset or Liability of the other Party (or member of its Group) shall be held by such Party in trust for the use and benefit of the Party entitled thereto and, promptly upon receipt by such Party of any such payment or reimbursement, such Party shall pay over, or shall cause the applicable member of its Group to pay over to the other Party the amount of such payment or reimbursement without right of set-off.

 

Section 2.5            Novation of R&DCo Liabilities.

 

(a)           R&DCo shall use its reasonable best efforts to obtain, or to cause to be obtained, as soon as practicable following the Distribution, any consent, substitution, approval, release or amendment requested by Ikaria required to novate or assign to the applicable Person in the R&DCo Group all obligations under agreements, leases, licenses and other obligations or Liabilities of any nature whatsoever that constitute R&DCo Liabilities, or to obtain in writing the unconditional release of all parties to such arrangements other than any Person in the R&DCo Group, so that, in any such case, the R&DCo Group Members will be solely responsible for such Liabilities; provided, however, that neither Ikaria nor R&DCo shall be obligated to pay any consideration therefor to any third party from whom such consents, approvals, substitutions, amendments and releases are requested; provided further, however, that any legal fees or other administrative costs associated with obtaining such consents, approvals, substitution, amendments and releases shall be borne by R&DCo.

 

(b)           If R&DCo is unable to obtain, or to cause to be obtained, any such required consent, substitution, approval, release or amendment, the applicable Person in the Ikaria Group shall continue to be bound by such agreements, leases, licenses and other obligations that constitute R&DCo Liabilities and, unless not permitted by Law or the terms thereof, R&DCo shall cause a Person in the R&DCo Group, as agent or subcontractor for such Person in the Ikaria Group, to pay, perform and discharge fully all such obligations or other Liabilities of Ikaria or such other Person that constitute R&DCo Liabilities thereunder from and after the Distribution. R&DCo shall indemnify each Ikaria Indemnified Party and hold each of them harmless against any Liabilities arising in connection therewith. Ikaria shall, without further consideration, pay or remit, or cause to be paid or remitted, to R&DCo promptly all money, rights and other consideration received by it or any Person in the Ikaria Group in respect of such performance. If and when any such consent, approval, release, substitution or amendment shall be obtained or such agreement, lease, license or other rights or obligations shall 

 

17

 

otherwise become assignable or able to be novated, Ikaria shall thereafter assign, or cause to be assigned, all its rights, obligations and other Liabilities thereunder or any rights or obligations of any Person in its Group to R&DCo (or to an R&DCo Group Member designated by R&DCo) without payment of further consideration, and R&DCo, without the payment of any further consideration, shall or shall cause its designee to, assume such rights and obligations.

 

Section 2.6            Novation of Ikaria Liabilities.

 

(a)           Ikaria shall use its reasonable best efforts to obtain, or to cause to be obtained, as soon as practicable following the Distribution, any consent, substitution, approval, release or amendment requested by R&DCo required to novate or assign to the applicable Person in the Ikaria Group all obligations under agreements, leases, licenses and other obligations or Liabilities of any nature whatsoever that constitute Ikaria Liabilities, or to obtain in writing the unconditional release of all parties to such arrangements other than any Person in the Ikaria Group, so that, in any such case, the Ikaria Group Members will be solely responsible for such Liabilities; provided, however, that neither Ikaria nor R&DCo shall be obligated to pay any consideration therefor to any third party from whom such consents, approvals, substitutions, amendments and releases are requested; provided further, however, that any legal fees or other administrative costs associated with obtaining such consents, approvals, substitution, amendments and releases shall be borne by Ikaria.

 

(b)           If Ikaria is unable to obtain, or to cause to be obtained, any such required consent, substitution, approval, release or amendment, the applicable Person in the R&DCo Group shall continue to be bound by such agreements, leases, licenses and other obligations that constitute Ikaria Liabilities and, unless not permitted by Law or the terms thereof, Ikaria shall cause a Person in the Ikaria Group, as agent or subcontractor for such Person in the R&DCo Group, to pay, perform and discharge fully all such obligations or other Liabilities of R&DCo or such other Person that constitute Ikaria Liabilities thereunder from and after the Distribution. Ikaria shall indemnify each R&DCo Indemnified Party and hold each of them harmless against any Liabilities arising in connection therewith. R&DCo shall, without further consideration, pay or remit, or cause to be paid or remitted, to Ikaria promptly all money, rights and other consideration received by it or any Person in the R&DCo Group in respect of such performance. If and when any such consent, approval, release, substitution or amendment shall be obtained or such agreement, lease, license or other rights or obligations shall otherwise become assignable or able to be novated, R&DCo shall thereafter assign, or cause to be assigned, all its rights, obligations and other Liabilities thereunder or any rights or obligations of any Person in its Group to Ikaria (or to an Ikaria Group Member designated by Ikaria) without payment of further consideration, and Ikaria, without the payment of any further consideration shall, or shall cause its designee to, assume such rights and obligations.

 

18

 

ARTICLE 3
 THE DISTRIBUTION

 

Section 3.1            The Distribution.

 

(a)           Ikaria shall effect the Distribution in accordance with the terms of the Merger Agreement.  The Distribution shall involve the following steps:

 

(i)          On or prior to the date hereof, AcquisitionCo shall have effected the Initial Distribution by distributing to Ikaria, by means of a special dividend, 1% of the outstanding R&DCo Voting Units.

 

(ii)         Following the Initial Distribution but prior to the Merger Closing, Ikaria shall effect the Stock Conversion by causing the filing of a Certificate of Amendment to Ikaria’s Restated Certificate of Incorporation, pursuant to which all outstanding shares of Ikaria’s preferred stock, par value $0.01 per share, and non-voting common stock, par value $0.01 per share, shall convert into shares of Ikaria’s voting common stock, par value $0.01 per share.

 

(iii)        Following the Stock Conversion, Ikaria shall effect the 1% Distribution by distributing by means of a special dividend to the holders of outstanding shares of Ikaria Capital Stock as of the Record Date, the R&DCo Voting Units received by Ikaria in the Initial Distribution.  Such special dividend shall be paid to the holders of Ikaria Capital Stock on a pro rata basis based on each such holder’s pro rata ownership of Ikaria Capital Stock, with each such holder receiving 1% of one R&DCo Voting Unit for each share of Ikaria voting common stock held by such Ikaria stockholder on the Record Date.

 

(iv)        Immediately following the 1% Distribution, AcquisitionCo shall effect the LLC Conversion pursuant to which AcquisitionCo shall convert from a Delaware corporation into a Delaware limited liability company.

 

(v)         Following the LLC Conversion but prior to the Merger Closing, AcquisitionCo shall distribute to Ikaria, by means of a special dividend, the remaining R&DCo Voting Units held by AcquisitionCo.

 

(vi)        Immediately thereafter, Ikaria shall effect the 99% Distribution by distributing by means of a special dividend to the holders of outstanding shares of Ikaria Capital Stock as of the Record Date, such R&DCo Voting Units.  Such special dividend shall be paid to the holders of Ikaria Capital Stock on a pro rata basis based on each such holder’s pro rata ownership of Ikaria Capital Stock, with each such holder receiving 99% of one R&DCo Voting Unit for each share of Ikaria voting common stock held by such Ikaria stockholder on the Record Date.

 

(b)           In addition, in connection with the Distribution and prior to the Distribution Date:

 

(i)          the exercise price of all outstanding Ikaria Stock Options will be adjusted downward to reflect the impact of the Distribution on the value of Ikaria, and options to purchase R&DCo Non-Voting Units will be distributed to holders of outstanding Ikaria Stock Options with exercise prices that are based on the value ascribed to R&DCo in the Distribution, all as set forth more fully in Article VII of the Employee Matters Agreement; provided that each holder of an outstanding Ikaria Stock Option that is neither an Accredited Investor nor an employee of Ikaria will receive, in lieu of each such options to purchase R&DCo Non-Voting 

 

19

 

Units, an amount in cash equal to the difference between the fair market value of an R&DCo Non-Voting Unit (as determined by R&DCo) less the exercise price of the options to purchase R&DCo Non-Voting Units, less applicable withholding taxes, which R&DCo shall pay (or cause to be paid) to the holder promptly following completion of the Distribution; and

 

(ii)         each holder of an Ikaria RSU shall receive an award consisting of the same number of restricted Non-Voting Units of R&DCo as were subject to the Ikaria RSU, as set forth more fully in Article VII of the Employee Matters Agreement.

 

(c)           Subject to the terms of the Merger Agreement and with the prior written consent of Purchaser (not to be unreasonably withheld), Ikaria may, at any time and from time to time until the completion of the Distribution, modify or change the terms of the Distribution, including by accelerating or delaying the timing of the consummation of all or part of the Distribution.  R&DCo shall cooperate with Ikaria in all respects to accomplish the Distribution and shall, at Ikaria’s direction, promptly take any and all actions necessary or desirable to effect the Distribution. For the avoidance of doubt, if the Merger Agreement is terminated in accordance with its terms prior to the Closing as defined therein, Ikaria shall have the right not to complete all or any portion of the Distribution for any or no reason.

 

Section 3.2            Actions Prior to the Distribution.  In connection with the Distribution, the Parties shall take the actions set forth in this Section 3.2.

 

(a)           Ikaria and R&DCo shall prepare and mail, prior to any Distribution Date, to the holders of Ikaria Capital Stock, such information concerning R&DCo and the Distribution and such other matters as Ikaria reasonably determines is necessary or desirable.

 

(b)           R&DCo shall use reasonable best efforts to take all such action as may be necessary or desirable under applicable federal and state securities and blue sky Laws of the United States (and any comparable Laws under any foreign jurisdictions) in connection with the Distribution.

 

Section 3.3            Certain Stockholder Matters.

 

(a)           On or prior to the Distribution Date, Ikaria shall deliver to R&DCo true, correct and complete copies of the stock and transfer records reflecting the holders of Ikaria Capital Stock entitled to receive R&DCo Voting Units in connection with the Distribution.  On the Distribution Date or as soon as reasonably practicable thereafter, Ikaria shall provide notice to each such holder or designated transferee(s) of such holder of the number of R&DCo Voting Units distributed to such holder in the Distribution.  Ikaria and R&DCo shall cooperate with each other in connection with all aspects of the Distribution and all other matters relating to the issuance of the R&DCo Voting Units to be distributed to the holders of Ikaria Capital Stock in connection with the Distribution.

 

(b)           Effective immediately upon the 1% Distribution, each Person described in Sections 3.1(a)(iii) and (vi) that acquires an R&DCo Voting Unit shall be admitted as a Member under the R&DCo LLC Agreement and shall be treated as a “Member” for all purposes thereunder.

 

20

 

(c)           From and after the Distribution, R&DCo shall regard each Person described in Sections 3.1(a)(iii) and (vi) that is entitled to receive such R&DCo Voting Units as the record holder of R&DCo Voting Units received in accordance with the terms of the Distribution without requiring any action on the part of such Person, until such time as such Person shall have duly transferred the R&DCo Voting Units received in the Distribution in accordance with applicable Law or any other applicable restrictions including restrictions under the R&DCo LLC Agreement.  R&DCo agrees that, until any transfer of such R&DCo Voting Units is validly effected, each such holder shall be entitled to all rights and be subject to all obligations as a “Member” under the R&DCo LLC Agreement, including the right to receive all distributions payable on, and exercise voting rights (if any) and all other rights and privileges with respect to, the R&DCo Voting Units then held by such holder in accordance with the R&DCo LLC Agreement.

 

(d)           Ikaria shall be entitled to and shall deduct and withhold Taxes from the distribution of R&DCo Voting Units to holders of Ikaria Capital Stock pursuant to this Agreement as required by Law.  Any amount that is so deducted and withheld shall be paid over to the applicable Governmental Authority, and any such amount so deducted, withheld and paid shall be deemed for purposes of this Agreement to have been distributed to the Person in respect of which such amount was so deducted and withheld.

 

ARTICLE 4
 ACCESS TO INFORMATION; FINANCIAL STATEMENTS

 

Section 4.1            Restrictions on Disclosure of Information.

 

(a)           Generally.  Without limiting any rights or obligations under any other existing or future agreement between the Parties and/or any other members of their respective Group relating to confidentiality, for ten (10) years after the Distribution each Party shall, and each Party shall cause its respective Group Members and use its reasonable best efforts to cause its Representatives to, hold in confidence, with at least the same degree of care that applies to Ikaria’s confidential and proprietary Information pursuant to policies in effect as of the Distribution Date, all confidential and proprietary Information concerning the other Group that is either in its possession as of the Distribution or furnished by the other Group or its respective Representatives at any time pursuant to this Agreement, any Ancillary Document or the transactions contemplated hereby or thereby. Notwithstanding the foregoing, each Party, its respective Group Members and its Representatives, may disclose such Information to the extent that such Party can demonstrate that such Information is or was (i) in the public domain other than by the breach of this Agreement or by breach of any other agreement between or among the Parties and/or any of their respective Group Members relating to confidentiality or (ii) lawfully acquired from a third Person on a non-confidential basis or independently developed by, or on behalf of, such Party by Persons who do not have access to, or descriptions of, any such Information.  Each Party shall maintain, and shall cause its respective Group Members and use its reasonable best efforts to cause its Representatives to maintain, policies and procedures, and develop such further policies and procedures as shall from time to time become necessary or appropriate, to ensure compliance with this Section 4.1. Nothing in this Article 4 shall be deemed 

 

21

 

to limit INO Therapeutics’ or Pulse Technologies’ exercise of their respective rights under the R&DCo Cross License Agreement.

 

(b)           Disclosure of Third-Person Information.  R&DCo acknowledges that it and other R&DCo Group Members may have in its or their possession confidential or proprietary Information of third Persons that was received under confidentiality or non-disclosure agreement with such third Person while part of Ikaria. R&DCo shall, and R&DCo shall cause its respective Group Members and use its reasonable best efforts to cause its and their respective Representatives to, hold in confidence the confidential and proprietary Information of third Persons to which any R&DCo Group Member has access, in accordance with the terms of any agreements entered into prior to the Distribution between Ikaria Group Members (whether acting through, on behalf of, or in connection with, the R&DCo Business) and such third Persons.

 

Section 4.2            Protective Arrangements.  If either Party or any of its respective Group Members or Representatives becomes required to or has received a request to make a Required Disclosure of any Information that it is otherwise obligated to hold in confidence pursuant to Section 4.1, such Party shall notify the other Party prior to disclosing or providing such Information and shall cooperate at the expense of such other Party in seeking any reasonable protective arrangements (including by seeking confidential treatment of such Information) requested by such other Party (it being understood that, with respect to the Required Disclosure of any Information of a third Person described in Section 4.1(b), Ikaria hereby authorizes the applicable R&DCo Group Members to notify the applicable third Person to satisfy any applicable review or consent requirements or to arrange for any appropriate protective arrangements).  Subject to the foregoing, the Party that is (or whose Group Members are) required or requested to make such Required Disclosure may thereafter disclose or provide Information to the extent required or requested (as contemplated by the definition of “Required Disclosure”); provided that, upon request, such Party (or its Group Member) provides the other Party with a copy of the Information so disclosed in the format so disclosed.  Notwithstanding the foregoing, a Party or its respective Group Members may make any public disclosure it believes in good faith is required by applicable securities laws, regulations or stock market rules, provided that such Party or Group Member uses reasonable efforts to advise the other Party of such disclosure and provide the other Party with a copy of the proposed disclosure prior to making the disclosure.

 

Section 4.3            Provision of Corporate Records; Access to Information.

 

(a)           As soon as practicable following the date hereof, to the extent not effectuated prior to the date hereof and subject to the provisions of this Section 4.3(a), Ikaria and R&DCo shall transition (i) to R&DCo all R&DCo Books and Records in the possession of any Ikaria Group Member, and (ii) to Ikaria all Ikaria Books and Records in the possession of any R&DCo Group Member.  The foregoing shall be limited by the following:

 

(i)          Each Party may retain copies of books and records delivered to the other, subject to such Party’s compliance with confidentiality obligations set forth in Section 4.1 with respect to the Information contained in such books and records.

 

22

 

(ii)         Neither Party shall be required to deliver to the other books and records or portions thereof that are (A) the subject of a confidentiality agreement between such Party and a third Person that prohibits disclosure to the other Party (provided, however, that if requested by the other Party, such Party shall use reasonable best efforts to seek a waiver of or other relief from such confidentiality agreement, it being understood that no Party shall be obligated to pay any consideration (or otherwise incur any Liability or obligation) therefor to any third Person from whom any such waiver is sought (unless such Party is fully reimbursed or otherwise made whole by the requesting Party)), or (B) prohibited from disclosure under applicable Law.

 

(b)           During the Retention Period, each Party shall cooperate with and afford, and shall cause its respective Group Members and use its reasonable best efforts to cause its Representatives to cooperate with and afford, to the other Party reasonable and timely access during normal business hours upon reasonable advance request to all Information (other than Information which is (i) protected from disclosure by the attorney-client privilege or work product doctrine, (ii) proprietary in nature, (iii) the subject of a confidentiality agreement between such Party and a third Person that prohibits disclosure to the other Party (provided, however, that if requested by the other Party, such Party shall use reasonable best efforts to seek a waiver of or other relief from such confidentiality agreement, it being understood that no Party shall be obligated to pay any consideration (or otherwise incur any Liability or obligation) therefor to any third Person from whom any such waiver is sought (unless such Party is fully reimbursed or otherwise made whole by the requesting Party)), or (iv) prohibited from disclosure under applicable Law (any such Information described in the foregoing clauses (i) through (iv), “Restricted Information”)) owned by such Party or one of its Group Members or within such Party’s or any of its respective Group Member’s or Representative’s possession which is created prior to the Distribution Date and which relates to the requesting Party’s (the “Requestor”) business, assets or liabilities, and such access is reasonably required by the Requestor (A) to comply with requirements imposed on the Requestor by any Law or Governmental Authority (including to make any Required Disclosure), (B) for use in preparation for or the prosecution or defense of any Action (except for any Action between the Parties or any of their respective Group Members), (C) to satisfy audit, accounting, Tax or similar requirements, (D) to obtain insurance, or (E) to comply with the Requestor’s obligations under this Agreement or any Ancillary Document.  As used in this Agreement, “access” shall mean the obligation of a Party in possession of Information (the “Possessor”) requested by the Requestor to exert reasonable best efforts to locate all requested Information that is owned and/or possessed by Possessor or any respective Group Members or Representatives.  The Possessor, at its own expense, shall conduct a diligent search designed to identify all requested Information and shall collect all such Information for inspection by the Requestor during normal business hours at the Possessor’s place of business.  Subject to such confidentiality and/or security obligations as the Possessor may reasonably deem necessary, the Requestor may have all requested Information duplicated at Requestor’s expense.  Alternatively, the Possessor may choose to deliver, at the Requestor’s expense, all requested Information to the Requestor in the form requested by the Requestor.  The Possessor shall notify the Requestor in writing at the time of delivery if such Information is to be returned to the Possessor.  In such case, the Requestor shall return such Information when no longer needed to the Possessor at the Possessor’s expense. In connection with providing Information pursuant to this Section 4.3, each Party shall, upon the request of the other Party and 

 

23

 

upon reasonable advance notice, make available during normal business hours its respective employees (and those employees of its respective Group Members and Representatives, as applicable) to the extent that they are reasonably necessary to discuss and explain all requested Information with and to the Requestor.

 

Section 4.4            Record Retention.  During the Retention Period, R&DCo shall, and R&DCo shall cause each of the other R&DCo Group Members to, adopt and comply with a record retention policy with respect to Information owned by or in the possession of the R&DCo Group and which is created prior to the Distribution Date that is no less stringent than Ikaria’s record retention policy in effect as of the Distribution Date.  During the Retention Period, Ikaria shall, and shall cause each of the other Ikaria Group Members to, maintain a record retention policy with respect to Information owned by or in the possession of the Ikaria Group and which is created prior to the Distribution Date that is no less stringent than Ikaria’s record retention policy in effect as of the Distribution.  Each Party shall, at its sole cost and expense, preserve and retain all Information in its respective possession or control that the other Party has the right to access pursuant to Section 4.3 or that it is required to preserve and retain in accordance with such record retention policy for a minimum of seven years or for any longer period as may be required by (a) any Governmental Authority, (b) any litigation matter, (c) applicable Law, or (d) any Ancillary Document (as applicable, the “Retention Period”). If either Party wishes to dispose of any Information that it is obligated to retain under this Section 4.4 prior to the expiration of the Retention Period, then that Party shall first provide 45 days’ written notice to the other Party, and the other Party shall have the right, at its option but at the expense of the Party that desires to dispose of such Information, upon prior written notice within such 45-day period, to take possession of such Information within 90 days after the date of the notice provided pursuant to this Section 4.4. Written notice of intent to dispose of such Information shall include a description of the Information in detail sufficient to allow the other Party to reasonably assess its potential need to retain such materials.

 

Section 4.5            Production of Witnesses.  After the Distribution, each Party shall use reasonable best efforts, and shall cause each of its respective Group Members to use reasonable best efforts, to make available to each other, upon written request, its past and present Representatives as witnesses to the extent that any such Representatives may reasonably be required (giving consideration to the business demands upon such Representatives) in connection with preparing for, defending or prosecuting any legal, administrative or other proceedings in which the requesting Party may from time to time be involved.  The obligation to provide witnesses pursuant to this Section 4.5 is intended to be interpreted in a manner so as to facilitate cooperation and shall include the obligation to provide as witnesses inventors and other officers without regard to whether the witness or the employer of the witness could assert a possible business conflict.  In connection with any matter contemplated by this Section 4.5 or any Information provided under Section 4.3 for use in a litigation, the Parties will enter into a mutually acceptable joint defense agreement so as to maintain to the extent practicable any applicable attorney-client privilege or work product immunity of any member of any Group.

 

24

 

Section 4.6            Financial Statements and Accounting.

 

(a)           The Parties agree to use their reasonable best efforts to complete, with the assistance of the Parties’ respective independent auditors, the Required R&DCo Financial Statements as promptly as practicable following the Distribution Date.  For the avoidance of doubt, R&DCo (in consultation with its independent auditors) shall control the preparation and content of the Required R&DCo Financial Statements.  In furtherance of the covenant set forth in the first sentence of this Section 4.6(a), Ikaria (i) shall and shall cause its Group Members and use its reasonable best efforts to cause its Representatives to provide access to all Information and (ii) shall use reasonable best efforts to cause its independent auditors to provide all assistance, in each case, as is reasonably required for purposes of completing the Required R&DCo Financial Statements in a timely manner.

 

(b)           Without limiting the generality of Section 4.3 above, each Party agrees, on a timely basis, during normal business hours and upon reasonable advance request of the other Party, to provide to the other Party and its Representatives and/or to provide the other Party and its Representatives with access to, all Information reasonably required in connection with (A) the closing of the books and the preparation and audit of each Party’s financial statements as of and for the year ended December 31, 2013, and (B) if and to the extent required under applicable Law: (I) each Party’s management assessment of internal controls over financial reporting as of December 31, 2013, (II) the audit thereof by such Party’s independent auditors and (III) each Party’s management assessment of disclosure controls and procedures as of December 31, 2013 (the items described in the foregoing subclauses (I) through (III), the “Control Assessments and Audit”).  Without limiting the generality of the foregoing, each Party will provide all required financial and other Information with respect to itself and its Group Members to its independent auditors within a sufficient and reasonable time and in reasonably sufficient detail to permit its independent auditors to take all steps and perform all reviews necessary to provide sufficient assistance to the other Party’s independent auditors with respect to Information to be included or contained in the other Party’s annual financial statements and to permit such other Party’s independent auditors and management to complete the Control Assessments and Audit, if and to the extent required under applicable Law.  Notwithstanding the foregoing, this Section 4.6(b) shall not require either Party to provide the other Party with any Restricted Information.

 

(c)           Each Party (the “First Party”) authorizes its respective independent auditors (the “First Party’s Auditors”) to make available to the other Party’s independent auditors (the “Other Party’s Auditors”) both the personnel who performed, or are performing, the annual audit of the First Party for the year ended December 31, 2013 and work papers related to such annual audit, within a reasonable time prior to the First Party’s Auditors’ opinion date, so that the Other Party’s Auditors are able to perform the procedures they consider necessary to take responsibility for the work of the First Party’s Auditors as it relates to the Other Party’s Auditors’ report on the other Party’s annual financial statements for the year ended December 31, 2013, all within sufficient time to enable the other Party to meet its timetable for the issuance and dissemination of such financial statements.

 

Section 4.7            Reimbursement.  Unless otherwise provided in this Article 4, each Party providing access to Information or witnesses to the other Party pursuant to Sections 4.3, 4.4, 4.5 

 

25

 

or 4.6(a) or (b) shall be entitled to receive from the receiving Party, upon the presentation of invoices therefor, payment for all reasonable costs and expenses (including allocated compensation, salary and overhead expenses) as may be reasonably incurred in providing such Information or witnesses. In furtherance of the foregoing, (a) R&DCo shall be liable for reimbursing Ikaria for the reasonable costs and expenses of Ikaria’s Auditors incurred by Ikaria in connection with the preparation of the Required R&DCo Financial Statements and (b) Ikaria shall be liable for reimbursing R&DCo for the reasonable costs and expenses of R&DCo’s Auditors incurred by R&DCo in connection with the assistance provided by the R&DCo Auditors pursuant to Section 4.6(c).

 

Section 4.8            Other Agreements Regarding Access to Information.  The rights and obligations of the Parties under this Article 4 are subject to any specific limitations, qualifications or additional provisions on the sharing, exchange or confidential treatment of Information set forth in this Agreement or any Ancillary Document.

 

Section 4.9            Limitations of Liability.  Except as otherwise provided in Article 6, no Person shall have any Liability in the event that any Information exchanged or provided pursuant to this Agreement is found to be inaccurate in the absence of willful misconduct by the Person providing such Information.

 

ARTICLE 5
 ADDITIONAL COVENANTS AND OTHER MATTERS

 

Section 5.1            Further Assurances.  Subject to the terms and conditions set forth elsewhere in this Agreement and the Ancillary Documents:

 

(a)           each Party shall use reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper or advisable to consummate and make effective the Separation, the Distribution and the other transactions contemplated hereby and by the Ancillary Documents, including using reasonable best efforts to, and, except to the extent restricted by Law, cooperating with the other Party to (i) obtain all Consents from any Governmental Authority or other third party necessary or advisable in connection with the consummation of the Separation, the Distribution and the other transactions contemplated hereby or by any Ancillary Document, (ii) avoid any Action by any Governmental Authority in connection with the consummation of the Separation, the Distribution and the other transactions contemplated hereby or by any Ancillary Document, and (iii) defend any Actions, whether judicial or administrative, challenging this Agreement or the consummation of the transactions contemplated hereby, including seeking to have any stay or temporary restraining order entered by any court or other Governmental Authority vacated or reversed;

 

(b)           at the request and expense of R&DCo, Ikaria shall execute and deliver, and shall cause applicable Ikaria Group Members to execute and deliver, to R&DCo and/or applicable R&DCo Group Members such other instruments of transfer, conveyance, assignment, substitution and confirmation and take such other actions as R&DCo may reasonably deem necessary or desirable in order to (i) transfer, convey and assign to R&DCo and the other R&DCo Group Members, as applicable, the R&DCo Assets, (ii) put R&DCo and the other 

 

26

 

R&DCo Group Members, as applicable, in actual possession and operating control thereof and (iii) permit R&DCo and the other R&DCo Group Members, as applicable, to exercise all rights with respect thereto;

 

(c)           at the request and expense of Ikaria, R&DCo shall execute and deliver, and shall cause applicable R&DCo Group Members to execute and deliver, to Ikaria and/or applicable Ikaria Group Members such other instruments of transfer, conveyance, assignment, substitution and confirmation and take such other actions as Ikaria may reasonably deem necessary or desirable in order to (i) transfer, convey and assign to Ikaria and the other Ikaria Group Members, as applicable, the Ikaria Assets, (ii) put Ikaria and the other Ikaria Group Members, as applicable, in actual possession and operating control thereof and (iii) permit Ikaria and the other Ikaria Group Members, as applicable, to exercise all rights with respect thereto;

 

(d)           at the request and expense of Ikaria, R&DCo shall execute and deliver, and shall cause the applicable R&DCo Group Members to execute and deliver, to Ikaria and/or applicable Ikaria Group Members all instruments, assumptions, novations, undertakings, substitutions or other documents and take such other action as Ikaria may reasonably deem necessary or desirable in order to ensure that R&DCo and the other R&DCo Group Members fully and unconditionally assume and discharge the R&DCo Liabilities as contemplated under this Agreement, the Ancillary Documents or any document in connection herewith or therewith; and

 

(e)           at the request and expense of R&DCo, Ikaria shall execute and deliver, and shall cause the applicable Ikaria Group Members to execute and deliver, to R&DCo and/or applicable R&DCo Group Members all instruments, assumptions, novations, undertakings, substitutions or other documents and take such other action as R&DCo may reasonably deem necessary or desirable in order to ensure that Ikaria and the other Ikaria Group Members fully and unconditionally assume and discharge the Ikaria Liabilities as contemplated under this Agreement, the Ancillary Documents or any document in connection herewith or therewith.

 

Section 5.2            Performance.  Ikaria shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth in this Agreement or in any Ancillary Document to be performed by any Ikaria Group Member.  R&DCo shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth in this Agreement or in any Ancillary Document to be performed by any R&DCo Group Member.  Each Party further agrees that it shall cause its other Group Members not to take any action or fail to take any action inconsistent with such Party’s obligations under this Agreement, any Ancillary Document or the transactions contemplated hereby or thereby.

 

Section 5.3            [Intentionally Omitted.]

 

Section 5.4            Insurance Matters.  R&DCo acknowledges and agrees that from and after the Distribution Date (a) no Ikaria Group Member shall purchase or maintain, or cause to be purchased or maintained, any insurance policy for the protection of R&DCo or any R&DCo Group Member or any of their respective directors and officers, and (b) the R&DCo Group shall 

 

27

 

purchase insurance coverage sufficient to protect its interests and to comply with the requirements of the R&D Cross-License Agreement.

 

Section 5.5            Signs; Use of Names.  Except as otherwise contemplated by this Agreement or any Ancillary Document, prior to the Distribution Date, the Parties shall remove (or, if necessary, on an interim basis, cover up) any and all exterior and interior signs and identifiers on any R&DCo Asset that refer or pertain to any Ikaria Group Member or the Ikaria Business, or on any Ikaria Asset that refer or pertain to R&DCo or the R&DCo Business.  After the Distribution, (a) no R&DCo Group Member shall use or display any Ikaria Name, or any variations thereof, or other Trademarks using any of such names or otherwise owned by or licensed to any Ikaria Group Member that have not been assigned or licensed to such R&DCo Group Member, and (b) no Ikaria Group Member shall use or display any Trademarks owned by or licensed to any R&DCo Group Member that have not been assigned or licensed to such Ikaria Group Member, without the prior written consent of the other Party; provided, that notwithstanding the foregoing, nothing contained in this Agreement shall prevent either Party from using the other’s name in public filings with Governmental Authorities, materials intended for distribution to either Party’s stockholders or members or any other communication in any medium that describes the relationship between the Parties or the respective businesses of the Parties, including materials distributed to employees relating to the transition of employee benefit plans and materials used in connection with any Post-Distribution Financing.

 

Section 5.6            Indemnification of R&DCo Officers and Directors.  From the Distribution Date until the sixth anniversary of the Distribution Date, R&DCo shall fulfill and honor in all respects its obligations pursuant to its constitutive documents or other agreements providing for the indemnification, advancement of expenses and exculpation from liability of each person who is now, or has been at any time prior to the date of this Agreement, or who becomes prior to the Distribution Date, a director or officer of R&DCo or any of its Subsidiaries, but only to the extent not fully covered by insurance maintained and paid for by R&DCo, it being intended that an insurer who would otherwise be obligated to pay any such claim shall not be relieved of the responsibility with respect thereto or, solely by virtue of the indemnification provision hereof, have any subrogation rights with respect thereto.

 

ARTICLE 6
 INDEMNIFICATION; MUTUAL RELEASE

 

Section 6.1            Indemnification by R&DCo Group.  Subject to the provisions hereof, R&DCo shall, and shall cause each other entity in the R&DCo Group as of the Distribution to, jointly and severally, indemnify, defend and hold harmless each Ikaria Group Member, each of their respective past and present Affiliates, directors, officers, employees and other Representatives, and each of their respective permitted successors and assigns (collectively, the “Ikaria Indemnified Parties”) from and against any and all Damages incurred or suffered by the Ikaria Indemnified Parties arising or resulting from the following, whether such Damages arise or accrue prior to, at or following the Distribution:

 

28

 

(a)           the failure of R&DCo or any other R&DCo Group Member or any other Person to pay, perform or otherwise properly discharge any of the R&DCo Liabilities in accordance with their respective terms;

 

(b)           the R&DCo Business or any R&DCo Liability;

 

(c)           the matters set forth on Schedule 6.1(c); and

 

(d)           any breach by R&DCo or any R&DCo Group Member of this Agreement or any Ancillary Document.

 

Notwithstanding anything to the contrary herein, in no event will any Ikaria Indemnified Party have the right to seek indemnification from any R&DCo Group Member with respect to any claim or demand against any Person in the Ikaria Group for satisfaction of any of the Ikaria Liabilities.

 

Section 6.2            Indemnification by Ikaria Group.  Subject to the provisions hereof, Ikaria shall, and shall cause each other entity in the Ikaria Group as of the Distribution to, jointly and severally, indemnify, defend and hold harmless each R&DCo Group Member, each of their respective past and present directors, officers and employees, and each of their respective permitted successors and assigns (collectively, the “R&DCo Indemnified Parties”) from and against any and all Damages incurred or suffered by the R&DCo Indemnified Parties arising or resulting from the following, whether such Damages arise or accrue prior to, at or following the Distribution:

 

(a)           the failure of Ikaria or any other Ikaria Group Member or any other Person to pay, perform or otherwise properly discharge any of the Ikaria Liabilities in accordance with their respective terms;

 

(b)           the Ikaria Business or any Ikaria Liability; and

 

(c)           any breach by Ikaria or any Ikaria Group Member of this Agreement or any Ancillary Document.

 

Notwithstanding anything to the contrary herein, in no event will any R&DCo Indemnified Party have the right to seek indemnification from any Ikaria Group Member with respect to any claim or demand against any Person in the R&DCo Group for satisfaction of any of the R&DCo Liabilities.

 

Section 6.3            Claim Procedure.

 

(a)           Claim Notice.  A Person that seeks indemnity under this Article 6 (an “Indemnified Party”) shall give written notice (a “Claim Notice”) to the Party from whom indemnification is sought (an “Indemnifying Party”), whether the Damages sought arise from matters solely between the Parties or from Third-Party Claims. With respect to matters solely between the Parties, the Claim Notice must contain (i) a description and, to the extent known, estimated amount (the “Claimed Amount”) of any Damages incurred or reasonably expected to 

 

29

 

be incurred by the Indemnified Party, (ii) a reasonable explanation of the basis for the Claim Notice to the extent of facts then known by the Indemnified Party, and (iii) a demand for payment of those Damages. No delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any Liability or obligation hereunder except to the extent that the Indemnifying Party is prejudiced by such delay or deficiency or the amount of any associated Damages is increased by such delay or deficiency.

 

(b)           Response to Notice of Claim. Within 30 days after delivery of a Claim Notice with respect to a matter solely between the Parties, the Indemnifying Party shall deliver to the Indemnified Party a written response in which the Indemnifying Party shall either: (i) agree that the Indemnified Party is entitled to receive all of the Claimed Amount and, in which case, the Indemnifying Party shall pay the Claimed Amount in accordance with a payment and distribution method reasonably acceptable to the Indemnified Party; or (ii) dispute that the Indemnified Party is entitled to receive all or any portion of the Claimed Amount.

 

(c)           Contested Claims. In the event that the Indemnifying Party disputes the Claimed Amount, such dispute shall be resolved in accordance with Article 7.  Upon ultimate resolution thereof, the Parties shall take such actions as are reasonably necessary to comply therewith.

 

(d)           Third-Party Claims.

 

(i)          In the event that the Indemnified Party receives notice or otherwise learns of the assertion by a Person who is not a member of either Group of any claim or the commencement of any Action (any such claim or Action, a “Third-Party Claim”) with respect to which the Indemnifying Party may be obligated to provide indemnification under this Article 6, the Indemnified Party shall give written notification to the Indemnifying Party of the Third-Party Claim.  Such notification shall be given promptly after receipt by the Indemnified Party of notice of such Third-Party Claim, shall be accompanied by reasonable supporting documentation submitted by such third party (to the extent then in the possession of the Indemnified Party) and shall describe in reasonable detail (to the extent known by the Indemnified Party) the facts constituting the basis for such Third-Party Claim and the amount of the claimed Damages (to the extent they can be reasonably estimated by the Indemnified Party based on available information); provided, however, that no delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any Liability or obligation hereunder except to the extent that the Indemnifying Party is prejudiced by such delay or deficiency or to the extent the amount of any associated Damages is increased by such delay or deficiency.  If, and for so long as, (A) the Indemnifying Party notifies the Indemnified Party as soon as practicable, but in no event later than 30 days, after delivery of such notification that the Indemnifying Party does not dispute the Indemnifying Party’s obligation to indemnify hereunder and desires to defend the Indemnified Party against such Third-Party Claim, and (B) the Third-Party Claim (I) does not involve criminal liability or any admission of wrongdoing, (II) does not seek equitable relief or any other material non-monetary remedy against the Indemnified Party, (III) does not involve a claim which the Indemnified Party reasonably believes would have a material and adverse effect on the Indemnified Party’s business or (IV) is not one in which the Indemnifying Party is also a party and, in the opinion of the Indemnified Party’s outside counsel,

 

30

 

joint representation would be inappropriate or there may be legal defenses available to the Indemnified Party which are different from or additional to those available to the Indemnifying Party, then except as hereinafter provided, such Indemnifying Party shall have the right to defend against such Third-Party Claim by appropriate proceedings with legal counsel reasonably acceptable to the Indemnified Party, which proceedings shall be promptly settled or diligently prosecuted by the Indemnifying Party to a final conclusion.  During any period in which the Indemnifying Party has not so assumed control of such defense, the Indemnified Party shall control such defense and is hereby authorized (but not obligated) prior to and during such period to file any motion, answer or other pleading and to take any other action which the Indemnified Party shall deem necessary or appropriate to protect the Indemnified Party’s interests.

 

(ii)         The Party not controlling such defense (the “Non-controlling Party”) may participate therein at its own expense; provided, however, that if the Indemnifying Party assumes control of such defense and the Indemnified Party concludes, upon advice of counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests or different defenses available with respect to such Third-Party Claim, the reasonable fees and expenses of one additional counsel to the Indemnified Party shall be considered “Damages” for purposes of this Agreement.  The Party controlling such defense (the “Controlling Party”) shall keep the Non-controlling Party reasonably advised of the status of such Third-Party Claim and the defense thereof and shall consider in good faith recommendations made by the Non-controlling Party with respect thereto.  Subject to receiving a confidentiality undertaking from the Controlling Party and any redactions that the Non-controlling Party determines are advisable for purposes of maintaining privilege, the Non-controlling Party shall furnish the Controlling Party with such Information as it may have with respect to such Third-Party Claim (including copies of any summons, complaint or other pleading which may have been served on such Party and any written claim, demand, invoice, billing or other document evidencing or asserting the same) and shall otherwise cooperate with and assist the Controlling Party in the defense of such Third-Party Claim.

 

(iii)        The Indemnifying Party shall not agree to any settlement of, or the entry of any judgment arising from, any such Third-Party Claim without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that the consent of the Indemnified Party shall not be required if (A) such settlement involves only the payment of monetary damages and the Indemnifying Party agrees in writing to pay any amounts payable pursuant to such settlement or judgment, (B) such settlement or judgment includes a full, complete and unconditional release of the Indemnified Party and its Affiliates from further Liability and (C) such settlement involves no admission of wrongdoing by the Indemnified Party or its Affiliates. The Indemnified Party shall not agree to any settlement of, or the entry of any judgment arising from, any such Third-Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed.

 

Section 6.4            Survival; Limitations.

 

(a)           All covenants and agreements of the Parties contained in this Agreement shall survive each of the Separation and the Distribution.  The rights and obligations of Ikaria, 

 

31

 

R&DCo and each of their respective Indemnified Parties under this Agreement shall survive the sale, assignment or other transfer by any Party of any Assets, businesses or Liabilities, or the change of form or change of control of any Party.

 

(b)           The amount of any Damages for which indemnification is provided under this Agreement shall be net of any amounts actually recovered by the Indemnified Party from any third Person (including amounts actually recovered under insurance policies) with respect to such Damages (net of all costs and expenses, including collection costs and any retention amounts or increases in premiums).  An insurer who would otherwise be obligated to pay any claim shall not be relieved of the responsibility with respect thereto or, solely by virtue of the indemnification provision hereof, have any subrogation rights with respect thereto.

 

(c)           Unless otherwise required by applicable Law, the Parties agree that any indemnification payments made by one Party to another Party pursuant to this Agreement after the Distribution shall, to the extent permissible under applicable law, be treated for all Tax and financial accounting purposes as contributions or distributions, as appropriate, made immediately prior to the Distribution.  If it is determined that the receipt or accrual of any indemnification payment is subject to Tax, such payment shall be increased so that the amount of such increased payment reduced by the amount of all Taxes payable with respect to the receipt thereof (but taking into account all correlative Tax deductions resulting from the payment of the applicable Damages that gave rise to such indemnification payment) shall equal the amount of the payment which the Party receiving such payment would otherwise be entitled to receive pursuant to this Agreement.

 

(d)           Notwithstanding the joint and several indemnification obligations of each Group as set forth in Sections 6.1 and 6.2, the Parties agree that the indemnification obligation of any Ikaria Group Member or R&DCo Group Member, as applicable, for Damages shall be satisfied by a direct payment from Ikaria or R&DCo, as applicable, to the other Party irrespective of which Group Member is found liable for Damages.

 

(e)           Notwithstanding anything to the contrary in this Agreement, to the extent the Employee Matters Agreement specifically provides indemnification with respect to certain employee-related R&DCo Liabilities, the Employee Matters Agreement shall govern with respect to that indemnification. To the extent indemnification is not provided in the Employee Matters Agreement, the indemnification terms of this Agreement shall govern.

 

(f)            NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS GROUP MEMBERS BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, COLLATERAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS SUFFERED BY AN INDEMNIFIED PARTY, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, IN CONNECTION WITH ANY DAMAGES ARISING HEREUNDER OR THEREUNDER; PROVIDED, HOWEVER, THAT TO THE EXTENT AN INDEMNIFIED PARTY IS REQUIRED TO PAY ANY SPECIAL, INCIDENTAL, INDIRECT, COLLATERAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS TO A PERSON WHO IS NOT A MEMBER OF EITHER GROUP IN 

 

32

 

CONNECTION WITH A THIRD-PARTY CLAIM, OR INCURS ANY SPECIAL, INCIDENTAL, INDIRECT, COLLATERAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS AS A RESULT OF RESTRICTIONS OR LIMITATIONS IMPOSED ON AN INDEMNIFIED PARTY BY THE FDA AS A RESULT OF THE ACTS OR OMISSIONS OF (INCLUDING THE PROVISION OF ANY PRODUCT OR SERVICE BY) THE OTHER PARTY, SUCH DAMAGES SHALL CONSTITUTE DIRECT DAMAGES AND NOT SUBJECT TO THE LIMITATION SET FORTH IN THIS SECTION 6.4(f).

 

(g)           Notwithstanding a Party’s knowledge of any breach by the other Party of any representation, warranty, covenant or agreement contained in this Agreement or any Ancillary Document or any facts or circumstances potentially giving rise to a claim under this Agreement or any Ancillary Document (and regardless of how such Party shall have acquired such knowledge), such Party shall have the right to consummate the transactions provided for herein, and all of such Party’s rights and remedies shall be preserved without regard to its knowledge of such information.

 

(i)          Notwithstanding anything herein to the contrary, in no event shall any Indemnified Party be entitled to receive payment of Damages under this Agreement to the extent that such Indemnified Party has received payments in respect of such Damages pursuant to any rights to indemnification or otherwise under any Ancillary Documents.

 

Section 6.5            Non-Recourse.  All claims or causes of action (whether in contract or in tort, in law or in equity) that may be based upon, arise out of or related to this Agreement or any Ancillary Document, or the negotiation, execution or performance of this Agreement or such Ancillary Document (including any representation or warranty made in connection with this Agreement or such Ancillary Document or as an inducement to enter into this Agreement or such Ancillary Document), may be made only against the Persons that are expressly identified as parties thereto.  Except as provided for in Section 6.4, no Person who is not a named Party or is not named as a party to the applicable Ancillary Document, including any director, officer, employee, stockholder, member, Affiliate, agent or representative of any named Party or party to such Ancillary Document (“Non-Party Affiliates”), shall have any Liability (whether in contract or in tort, in law or in equity, or based upon any theory that seeks to impose Liability of an entity party against its owners or Affiliates) for any Liabilities arising under, in connection with or related to this Agreement or such Ancillary Document or for any claim based on, in respect of, or by reason of this Agreement or such Ancillary Document or its negotiation or execution; and each Party waives and releases all such Liabilities against any such Non-Party Affiliates.  Non-Party Affiliates are expressly intended as third-party beneficiaries of this Section 6.5.

 

ARTICLE 7
 DISPUTE RESOLUTION

 

Section 7.1            Disputes.  Except as otherwise specifically provided in any Ancillary Document, the procedures for discussion, negotiation and mediation set forth in this Article 7 shall apply to all disputes, controversies or claims (whether arising in contract, tort or otherwise) that may arise out of or relate to, or arise under or in connection with this Agreement or the transactions contemplated hereby (including all actions taken in furtherance of the transactions 

 

33

 

contemplated hereby on or prior to the date hereof), or the commercial or economic relationship of the parties relating hereto or thereto, between or among any Person in the Ikaria Group and any Person in the R&DCo Group.

 

Section 7.2            Escalation; Mediation.

 

(a)           It is the intent of the Parties to use their respective reasonable best efforts to resolve expeditiously any dispute, controversy or claim between or among them with respect to the matters covered by this Agreement or any Ancillary Document that may arise from time to time on a mutually acceptable negotiated basis. In furtherance of the foregoing, any Party involved in a dispute, controversy or claim with respect to such matters (except any matters covered by the Transition Services Agreement) may deliver a notice (an “Escalation Notice”) demanding an in person meeting involving representatives of the Parties at a senior level of management of the Parties (or if the Parties agree, of the appropriate strategic business unit or division within such entity). A copy of any such Escalation Notice shall be given to the General Counsel, or like officer or official, of each Party (which copy shall state that it is an Escalation Notice pursuant to this Agreement). Any agenda, location or procedures for such discussions or negotiations between the Parties may be established by the Parties from time to time; provided, however, that the Parties shall use their reasonable best efforts to meet within 30 days of the Escalation Notice.

 

(b)           If the Parties are not able to resolve the dispute, controversy or claim through the escalation process referred to above, then the matter shall be referred to mediation. The Parties shall retain a mediator to aid the Parties in their discussions and negotiations by informally providing advice to the Parties. Any opinion expressed by the mediator shall be strictly advisory and shall not be binding on the Parties, nor shall any opinion expressed by the mediator be admissible in any other proceeding. The mediator may be chosen from a list of mediators previously selected by the Parties or by other agreement of the Parties. Costs of the mediation shall be borne equally by the Parties, except that each Party shall be responsible for its own expenses. Mediation shall be a prerequisite to the commencement of any Action by either Party against any member of the other Party’s Group.

 

Section 7.3            Court Actions.  In the event that any Party, after complying with the provisions set forth in Section 7.2 above, desires to commence an Action, such Party, subject to Section 8.2, may submit the dispute, controversy or claim (or such series of related disputes, controversies or claims) to any court of competent jurisdiction as set forth in Section 8.2.

 

ARTICLE 8
 MISCELLANEOUS

 

Section 8.1            Governing Law.  The internal Laws of the State of Delaware (without giving effect to any choice or conflict of law provision or rule, whether of the State of Delaware or any other jurisdiction, that would cause the application of Laws of any jurisdiction other than those of the State of Delaware) shall govern the construction, interpretation and other matters arising out of or in connection with this Agreement and, unless expressly provided therein, each 

 

34

 

Ancillary Document, and each of the exhibits and schedules hereto and thereto (whether arising in contract, tort, equity or otherwise).

 

Section 8.2            Jurisdiction.  If any dispute, controversy or claim arises out of or in connection with this Agreement or any Ancillary Document, except as expressly contemplated by any Ancillary Document, the Parties irrevocably (and the Parties shall cause each other member of their respective Group to irrevocably) (a) consent and submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware, (b) waive any objection to that choice of forum based on venue or to the effect that the forum is not convenient, and (c) WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHT TO TRIAL OR ADJUDICATION BY JURY.  Either Party may make service on the other Party by sending or delivering a copy of the process to the other Party at the address and in the manner provided for the giving of notices in Section 8.3.  Nothing in this Section 8.2, however, shall affect the right to serve legal process in any other manner permitted by Law.

 

Section 8.3            Notices.  All notices and other communications under this Agreement or any Ancillary Document shall be in writing and shall be deemed duly delivered (a) four Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (b) one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable nationwide overnight courier service, or (c) on the date of confirmation of receipt (or, the first Business Day following such receipt if the date of such receipt is not a Business Day) of transmission by facsimile, in each case to the intended recipient as set forth below.

 

If to Ikaria:

 

INO Therapeutics LLC

Perryville III Corporate Park

53 Frontage Road, Third Floor

P. O. Box 9001

Hampton, NJ 08827

Attention:  General Counsel

 

If to AcquisitionCo:

 

Ikaria Acquisition Inc.

Perryville III Corporate Park

53 Frontage Road, Third Floor

P. O. Box 9001

Hampton, NJ 08827

Attention:  General Counsel (or Chief Executive Officer if there is no General Counsel)

 

If to R&DCo:

 

35

 

Bellerophon Therapeutics LLC
 Perryville III Corporate Park

53 Frontage Road, Third Floor

P. O. Box 9001

Hampton, NJ 08827

Attention:  General Counsel (or Chief Executive Officer if there is no General Counsel)

 

With a copy (which shall not constitute notice) to:

 

New Mountain Partners II, L.P.

c/o New Mountain Capital, L.L.C.

787 Seventh Avenue, 49th Floor

New York, New York

Attention: Matthew Holt

Email: MHolt@newmountaincapital.com

 

Any party may give any notice or other communication hereunder using any other means (including personal delivery, messenger service, ordinary mail or electronic mail), but no such notice or other communication shall be deemed to have been duly given unless and until it actually is received by the party for whom it is intended.  Any party may change the address to which notices and other communications hereunder are to be delivered by giving the other parties notice in the manner herein set forth.

 

Section 8.4            Binding Effect and Assignment.  This Agreement and each Ancillary Document binds and benefits the Parties and their respective permitted successors and assigns. Neither Party may assign any of its rights or delegate any of its obligations under this Agreement or any Ancillary Document without the written consent of the other Party and any assignment or attempted assignment in violation of the foregoing shall be null and void.  Notwithstanding the preceding sentence, either Party may, upon written notice, assign this Agreement and the Ancillary Documents (other than the R&D Cross License, which can only be assigned in accordance with its terms) in connection with a merger transaction in which such Party is not the surviving entity or the sale of all or substantially all of its assets; provided that the surviving party or acquirer in such transaction agrees in writing to assume and be bound by all of such Party’s obligations hereunder.

 

Section 8.5            Severability.  Any term or provision of this Agreement or any Ancillary Document that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or thereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.  If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified.  In the 

 

36

 

event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that shall achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

 

Section 8.6            Specific Performance.  The Parties agree that irreparable damage would occur in the event that any provision of this Agreement or any Ancillary Document were not performed in accordance with its specific terms or were otherwise breached.  It is accordingly agreed that either Party shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or any Ancillary Document and to enforce specifically the terms and provisions of this Agreement or any Ancillary Document, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they are entitled at law or in equity.  Each of the Parties agrees that it shall not oppose the granting of an injunction, specific performance and other equitable relief on the basis that (a) the Party seeking such remedy has an adequate remedy at law or (b) an award of specific performance is not an appropriate remedy for any reason at law or equity.

 

Section 8.7            Entire Agreement.  This Agreement, together with the Ancillary Documents and each of the exhibits and schedules appended hereto and thereto, constitutes the final agreement between the Parties, and is the complete and exclusive statement of the Parties’ agreement on the matters contained herein and therein. All prior and contemporaneous negotiations and agreements between the Parties with respect to the matters contained herein and therein are superseded by this Agreement and the Ancillary Documents, as applicable.  In the event of any conflict between (a) any provision in this Agreement, on the one hand, and (b) any specific provision in any Ancillary Document, on the other hand, pertaining to the subject matter of such Ancillary Document, the specific provisions in such Ancillary Document shall control over the provisions in this Agreement, as applicable.

 

Section 8.8            No Third-Party Beneficiaries.  Except for Purchaser, which from and after the Closing (as defined in the Merger Agreement) shall be a third party beneficiary of this Agreement, and except as expressly set forth in Section 6.5 (which may be enforced directly by any Non-Party Affiliate), neither this Agreement nor any Ancillary Document is intended, or shall be deemed, to confer any rights or remedies upon any Person other than the Parties and their respective Group Members, successors and permitted assigns, to create any agreement of employment with any Person or to otherwise create any third-party beneficiary hereto or thereto.

 

Section 8.9            Counterparts and Signature.  This Agreement may be executed in two counterparts (including by facsimile or by an electronic scan delivered by electronic mail), each of which shall be deemed an original but both of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to the other Party, it being understood that both Parties need not sign the same counterpart.

 

Section 8.10          Expenses.  Except as otherwise expressly provided in this Agreement or any Ancillary Document, following the Distribution, each Party will be responsible for its own 

 

37

 

fees, costs and expenses incurred in connection with the transactions contemplated by this Agreement and the Ancillary Documents.

 

Section 8.11          Amendment.  The Parties may amend this Agreement or any Ancillary Document only by a written agreement signed by the Party intended to be bound by the amendment and that identifies itself as an amendment to this Agreement or such Ancillary Document, as applicable.

 

Section 8.12          Waiver.  The Parties may waive a provision of this Agreement or an Ancillary Document only by a writing signed by the Party intended to be bound by the waiver.  A Party is not prevented from enforcing any right, remedy or condition in the Party’s favor because of any failure or delay in exercising any right or remedy or in requiring satisfaction of any condition, except to the extent that the Party specifically waives the same in writing.  A written waiver given for one matter or occasion is effective only in that instance and only for the purpose stated.  A waiver once given is not to be construed as a waiver for any other matter or occasion.  Any enumeration of a Party’s rights and remedies in this Agreement or any Ancillary Document is not intended to be exclusive, and a Party’s rights and remedies are intended to be cumulative to the extent permitted by Law and include any rights and remedies authorized in law or in equity.

 

Section 8.13          Authority; R&DCo Assets.  Each of the Parties represents to the other on behalf of itself and each of its other Group Members that (a) it and its Group Members have the corporate or other requisite power and authority to execute, deliver and perform this Agreement and each of the Ancillary Documents to which it is a party, (b) the execution, delivery and performance of this Agreement and each of the Ancillary Documents to which they are a party by it and its Group Members have been duly authorized by all necessary corporate or other action, (c) it and its Group Members have duly and validly executed and delivered this Agreement and each of the Ancillary Documents to which they are a party, and (d) this Agreement and each of the Ancillary Documents to which they are a party is a valid and binding obligation, enforceable against it or its applicable Group Member in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar Laws affecting creditors’ rights generally and general equitable principles. R&DCo, on behalf of itself and each of its other Group Members, represents to Ikaria that (i) none of the R&DCo Assets are used in or necessary for the Ikaria Business except as otherwise set forth on Schedule 8.13(a) hereto, (ii) R&DCo, together with its Subsidiaries, has, and immediately following the Distribution will have, cash and cash equivalents in an amount equal to or greater than $80 million less (x) the amount deposited in escrow by R&DCo pursuant to the terms of the Transition Services Agreement and (y) $10,000 in respect of the aggregate cash payments made by or on behalf of R&DCo to holders of Ikaria Stock Options who immediately prior to the Distribution were neither employees of Ikaria nor Accredited Investors, pursuant to the terms of the Employee Matters Agreement (collectively, the “R&DCo Option Payments”), and (iii) the transactions contemplated by this Agreement do not require the consent, approval or authorization of any Person (before giving effect to the provisions of Section 2.3) except as set forth on Schedule 8.13(b).

 

38

 

Section 8.14          Construction of Agreement.

 

(a)           Where this Agreement or any Ancillary Document states that a Party “will” or “shall” perform in some manner or otherwise act or omit to act, it means that the Party is legally obligated to do so in accordance with this Agreement or such Ancillary Document, as applicable.

 

(b)           The captions, titles and headings, and table of contents, included in this Agreement and the Ancillary Documents are for convenience only, and do not affect this Agreement’s or such Ancillary Documents’ construction or interpretation.  When a reference is made in this Agreement or any Ancillary Document to an Article or a Section, exhibit or schedule, such reference shall be to an Article or Section of, or an exhibit or schedule to, this Agreement or such Ancillary Document, as applicable, unless otherwise indicated.

 

(c)           When used in this Agreement or any Ancillary Document, the words “including,” “includes,” or “include” shall be deemed to be followed by the phrase “without limitation.”

 

(d)          Any reference in this Agreement or any Ancillary Document to the singular includes the plural where appropriate.  Any reference in this Agreement or any Ancillary Document to the masculine, feminine or neuter gender includes the other genders where appropriate. Any reference in this Agreement or any Ancillary Document to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are permitted by this Agreement.  For purposes of this Agreement, after the Distribution the R&DCo Business shall be deemed to be the business of R&DCo and the R&DCo Group, and all references made in this Agreement to R&DCo as a party which operates as of a time following the Distribution, shall be deemed to refer to all R&DCo Group Members as a single party where appropriate.

 

(e)           Any agreement, instrument or statute defined or referred to in this Agreement, any Ancillary Document or in any agreement or instrument that is referred to in this Agreement or any Ancillary Document means such agreement, instrument or statue as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession or comparable successor statutes and references to all attachments thereto and instruments incorporated therein.

 

(f)            Any reference to any federal, state, local, or foreign Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise.

 

(g)           Unless otherwise expressly specified in an Ancillary Document, all references in this Agreement or any Ancillary Document to “dollars” or “$” means United States Dollars.  If any payment required to be made hereunder is denominated in a currency other than United States Dollars, such payment shall be made in United States Dollars and the amount thereof shall be computed using the exchange rate published by the Wall Street Journal on the date of payment (or if the Wall Street Journal is not published on such date, the last date prior thereto on which the Wall Street Journal was published).

 

39

 

(h)           Unless otherwise expressly provided, wherever the consent of a Party is required or permitted herein, such consent may be withheld in such Party’s sole and absolute discretion.

 

Section 8.15          Termination.  This Agreement may be terminated at any time after the Distribution, by the mutual written consent of Ikaria and R&DCo.  In the event of a termination of this Agreement pursuant to the foregoing sentence, neither Party shall have any liability of any kind to the other Party under this Agreement, except for any breach of this Agreement that occurs prior to such termination.

 

Section 8.16          Insurance.  R&DCo, at its expense, shall hold and maintain in full force and effect a policy or policies of appropriate insurance coverage as reasonably determined by R&DCo, such insurance coverage (i) to include at a minimum products liability coverage and clinical trial liability coverage and (ii) to provide coverage amounts as are reasonable for the activities to be conducted by R&DCo but in no event less than $[**] of combined coverage for the products liability coverage and clinical trial liability coverage.  Each policy of insurance maintained by R&DCo shall name Ikaria as an additional insured.  All insurance shall be on an occurrence basis, and not on a claims made basis, except to the extent that occurrence basis insurance is not available on commercially reasonable terms.  Each insurance policy shall provide for a waiver of the insurer’s subrogation rights against R&DCo, to the extent such a waiver is permitted by the insurer.  At the request of Ikaria, R&DCo shall provide Ikaria with documentary evidence of compliance with its obligations under this Section including a copy of its current insurance certification and full policy details, and provide Ikaria with notice of any change to such policies within thirty (30) days from the effective date of such change.  The obligations of R&DCo under this Section 8.16 shall terminate at such time as Ikaria is no longer manufacturing and supplying nitric oxide delivery devices or nitric oxide for inhalation and corresponding placebo to any R&DCo Group Member pursuant to the Manufacturing and Supply Agreements.

 

 (This space intentionally left blank)

 

40

 

IN WITNESS WHEREOF, each of Ikaria, R&DCo and ServicesCo has caused this Agreement to be executed on its behalf by a duly authorized officer on the date first set forth above.

 

 

	
IKARIA, INC. 
   a Delaware corporation
    	
 
    	
BELLEROPHON   THERAPEUTICS LLC 
   a Delaware limited liability company
    
	
 
    	
 
    	
 
    
	
By:  
    	
/s/ Anastasios   Konidaris
    	
 
    	
By:  
    	
/s/ Daniel Tassé
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name: 
    	
Anastasios   Konidaris
    	
 
    	
Name: 
    	
Daniel Tassé
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title: 
    	
Chief Financial   Officer
    	
 
    	
Title: 
    	
Chief Executive   Officer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 IKARIA ACQUISITION INC. 
   a Delaware corporation
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Matthew M.   Bennett
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Name: 
    	
Matthew M. Bennett
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Title: 
    	
Vice President   & Secretary
    	
 
    	
 
    

 

 

[Signature Page to Separation and Distribution Agreement]

 

 

Schedule 1.1(a)

 

Ikaria Names

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	

    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
85/915,731
    	
 
    	
04/26/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
INO   Therapeutics LLC
    
	

    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
85/915,748
    	
 
    	
04/26/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
INO   Therapeutics LLC
    
	
DSIR
    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
85/070,932
    	
 
    	
06/24/2010
    	
 
    	
4,003,732
    	
 
    	
07/26/2011
    	
 
    	
INO   Therapeutics LLC
    
	
IKARIA
    	
 
    	
United   States
    	
 
    	
5, 9,   10, 37, 42, 44
    	
 
    	
77/334,544
    	
 
    	
11/20/2007
    	
 
    	
3,778,583
    	
 
    	
04/20/2010
    	
 
    	
Ikaria, Inc.
    
	
FLEXTRANET
    	
 
    	
United   States
    	
 
    	
42
    	
 
    	
86/062,864
    	
 
    	
09/12/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
INO   Therapeutics LLC
    
	

    	
 
    	
United   States
    	
 
    	
5, 9,   10, 37, 42, 44
    	
 
    	
77/334,547
    	
 
    	
11/20/2007
    	
 
    	
3,778,584
    	
 
    	
04/20/2010
    	
 
    	
Ikaria, Inc.
    
	
IKARIA   ADVANCING CRITICAL CARE
    	
 
    	
United   States
    	
 
    	
5, 9,   10, 37, 42, 44
    	
 
    	
77/334,549
    	
 
    	
11/20/2007
    	
 
    	
3,778,585
    	
 
    	
04/20/2010
    	
 
    	
Ikaria, Inc.
    
	

    	
 
    	
United   States
    	
 
    	
5, 10,   42
    	
 
    	
77/257,398
    	
 
    	
08/16/2007
    	
 
    	
3,758,037
    	
 
    	
03/09/2010
    	
 
    	
Ikaria, Inc.
    
	

    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
79/026,694
    	
 
    	
04/04/2006
    	
 
    	
3,242,739
    	
 
    	
05/15/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
United   States
    	
 
    	
1
    	
 
    	
75/124,073
    	
 
    	
06/24/1996
    	
 
    	
2,109,970
    	
 
    	
10/28/1997
    	
 
    	
INO   Therapeutics LLC
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOCAL   CADDY
    	
 
    	
United   States
    	
 
    	
12
    	
 
    	
85/791,544
    	
 
    	
11/30/2012
    	
 
    	
4,389,669
    	
 
    	
08/20/2013
    	
 
    	
INO   Therapeutics LLC
    
	
INOCART
    	
 
    	
United   States
    	
 
    	
12
    	
 
    	
85/791,541
    	
 
    	
11/30/2012
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
75/342,495
    	
 
    	
08/18/1997
    	
 
    	
2,185,947
    	
 
    	
09/01/1998
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
79/026,770
    	
 
    	
04/04/2006
    	
 
    	
3,280,185
    	
 
    	
08/14/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX   DSIR
    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
85/071,349
    	
 
    	
06/25/2010
    	
 
    	
4,003,735
    	
 
    	
07/26/2011
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX   TOTAL CARE
    	
 
    	
United   States
    	
 
    	
37, 39,   41
    	
 
    	
85/737,439
    	
 
    	
09/25/2012
    	
 
    	
4,389,579
    	
 
    	
08/20/2013
    	
 
    	
INO   Therapeutics LLC
    
	
INOPULSE
    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
85/031,549
    	
 
    	
05/06/2010
    	
 
    	
3,893,703
    	
 
    	
12/21/2010
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
United   States
    	
 
    	
37, 39,   41
    	
 
    	
75/751,044
    	
 
    	
06/24/1999
    	
 
    	
2,678,500
    	
 
    	
01/21/2003
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
United   States
    	
 
    	
10
    	
 
    	
75/124,072
    	
 
    	
06/24/1996
    	
 
    	
2,100,392
    	
 
    	
09/23/1997
    	
 
    	
INO   Therapeutics LLC
    
	
NICU-PET
    	
 
    	
United   States
    	
 
    	
16, 41
    	
 
    	
85/836,260
    	
 
    	
01/30/2013
    	
 
    	
4,410,417
    	
 
    	
10/01/2013
    	
 
    	
INO   Therapeutics LLC
    
	
LUCASSIN
    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
79/006,270
    	
 
    	
10/19/2004
    	
 
    	
3,085,607
    	
 
    	
04/25/2006
    	
 
    	
Acorus   Therapeutics Limited
    
	
ONSTORVIS
    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
85/876474  Intent-to-use
    	
 
    	
03/14/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
Ikaria   Therapeutics LLC
    
	
TERLIVAZ
    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
85/876,469  Intent-to-use
    	
 
    	
03/14/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
Ikaria   Therapeutics LLC
    
	
IKARIA
    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
78/980,137
    	
 
    	
04/22/2005
    	
 
    	
3,443,089
    	
 
    	
06/03/2008
    	
 
    	
Ikaria, Inc.
    
	
IKARIA
    	
 
    	
United   States
    	
 
    	
10, 42
    	
 
    	
78/614,854
    	
 
    	
04/22/2005
    	
 
    	
3,450,879
    	
 
    	
06/17/2008
    	
 
    	
Ikaria, Inc.
    
	
IKARIA
    	
 
    	
United   States
    	
 
    	
10, 42
    	
 
    	
77/257,378
    	
 
    	
08/16/2007
    	
 
    	
3,811,308
    	
 
    	
06/29/2010
    	
 
    	
Ikaria, Inc.
    
	
IKARIA
    	
 
    	
United   States
    	
 
    	
10, 42
    	
 
    	
77/285,095
    	
 
    	
09/20/2007
    	
 
    	
3,811,324
    	
 
    	
06/29/2010
    	
 
    	
Ikaria, Inc.
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
COVOX
    	
 
    	
United   States
    	
 
    	
5
    	
 
    	
78/863,912
    	
 
    	
04/18/2006
    	
 
    	
3,314,528
    	
 
    	
10/16/2007
    	
 
    	
INO   Therapeutics LLC
    
	
IKARIA
    	
 
    	
Argentina
    	
 
    	
5
    	
 
    	
2895583
    	
 
    	
02/19/2009
    	
 
    	
2502255
    	
 
    	
05/04/2012
    	
 
    	
Ikaria   Holdings Inc.
    
	
IKARIA
    	
 
    	
Argentina
    	
 
    	
10
    	
 
    	
2895584
    	
 
    	
02/19/2009
    	
 
    	
2,339,735
    	
 
    	
01/06/2010
    	
 
    	
Ikaria   Holdings Inc.
    
	
I-N-O
    	
 
    	
Argentina
    	
 
    	
5
    	
 
    	
2012651
    	
 
    	
03/29/2007
    	
 
    	
2,201,350
    	
 
    	
12/12/2007
    	
 
    	
AGA   Aktiebolag
    
	

    	
 
    	
Argentina
    	
 
    	
10
    	
 
    	
2662580
    	
 
    	
04/10/2006
    	
 
    	
2,163,772
    	
 
    	
06/12/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOFLO
    	
 
    	
Argentina
    	
 
    	
5
    	
 
    	
2223956
    	
 
    	
06/11/1999
    	
 
    	
2,052,090
    	
 
    	
11/07/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Argentina
    	
 
    	
5
    	
 
    	
2209540
    	
 
    	
06/23/2010
    	
 
    	
2,446,383
    	
 
    	
06/13/2011
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Argentina
    	
 
    	
10
    	
 
    	
2656178
    	
 
    	
03/13/2006
    	
 
    	
2,158,935
    	
 
    	
05/17/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOVENT
    	
 
    	
Argentina
    	
 
    	
10
    	
 
    	
2990875
    	
 
    	
06/11/2012
    	
 
    	
2,509,164
    	
 
    	
06/11/2012
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Argentina
    	
 
    	
1
    	
 
    	
2035103
    	
 
    	
10/12/2007
    	
 
    	
2,237,520
    	
 
    	
07/08/2008
    	
 
    	
AGA   Aktiebolag
    
	
IKARIA
    	
 
    	
Australia
    	
 
    	
5, 9,   10, 37, 42, 44
    	
 
    	
1279359
    	
 
    	
12/24/2008
    	
 
    	
1279359
    	
 
    	
11/01/2010
    	
 
    	
Akaria   Inc.
    
	
I-N-O
    	
 
    	
Australia
    	
 
    	
5
    	
 
    	
649377
    	
 
    	
12/22/1994
    	
 
    	
649377
    	
 
    	
07/09/1996
    	
 
    	
INO   Therapeutics LLC
    
	
INOBlender
    	
 
    	
Australia
    	
 
    	
9, 10,   11
    	
 
    	
1133965
    	
 
    	
04/04/2006
    	
 
    	
1133965
    	
 
    	
01/08/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Australia
    	
 
    	
1
    	
 
    	
710276
    	
 
    	
06/07/1996
    	
 
    	
710276
    	
 
    	
06/13/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Australia
    	
 
    	
5
    	
 
    	
788810
    	
 
    	
03/22/1999
    	
 
    	
788810
    	
 
    	
01/14/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Australia
    	
 
    	
10, 11,   42
    	
 
    	
1134019
    	
 
    	
04/04/2006
    	
 
    	
1134019
    	
 
    	
01/29/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Australia
    	
 
    	
5, 10,   39, 41, 42
    	
 
    	
796442
    	
 
    	
06/04/1999
    	
 
    	
796442
    	
 
    	
08/25/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Australia
    	
 
    	
5
    	
 
    	
649372
    	
 
    	
12/22/1994
    	
 
    	
649372
    	
 
    	
08/13/1996
    	
 
    	
INO Therapeutics   LLC
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOVENT
    	
 
    	
Australia
    	
 
    	
10
    	
 
    	
710275
    	
 
    	
06/07/1996
    	
 
    	
710275
    	
 
    	
09/11/1998
    	
 
    	
INO   Therapeutics LLC
    
	
LUCASSIN
    	
 
    	
Australia
    	
 
    	
5
    	
 
    	
1362084
    	
 
    	
05/18/2010
    	
 
    	
13062084
    	
 
    	
01/10/2011
    	
 
    	
Ikaria   Therapeutics LLC
    
	
INOblender
    	
 
    	
Bolivia
    	
 
    	
10
    	
 
    	
06001228
    	
 
    	
11/27/2006
    	
 
    	
016623-C
    	
 
    	
11/27/2006
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Bolivia
    	
 
    	
5
    	
 
    	
086728
    	
 
    	
08/26/2006
    	
 
    	
105147-C
    	
 
    	
08/26/2006
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Bolivia
    	
 
    	
10
    	
 
    	
06000847
    	
 
    	
10/09/2006
    	
 
    	
105897-C
    	
 
    	
10/09/2006
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Bolivia
    	
 
    	
5
    	
 
    	
087904
    	
 
    	
08/01/2000
    	
 
    	
80368-C
    	
 
    	
08/01/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Bolivia
    	
 
    	
10
    	
 
    	
087906
    	
 
    	
06/06/2000
    	
 
    	
79014-C
    	
 
    	
06/06/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Bolivia
    	
 
    	
42
    	
 
    	
087910
    	
 
    	
06/06/2000
    	
 
    	
79018-C
    	
 
    	
06/06/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Brazil
    	
 
    	
10
    	
 
    	
821729209
    	
 
    	
06/21/1999
    	
 
    	
821729209
    	
 
    	
03/11/2003
    	
 
    	
 
    
	
INOVENT
    	
 
    	
Brazil
    	
 
    	
5, 7,   8, 9, 10, 11, 12, 14, 21, 22, 37, 42
    	
 
    	
819273082
    	
 
    	
07/01/1996
    	
 
    	
819273082
    	
 
    	
02/23/1999
    	
 
    	
INO   Therapeutics LLC
    
	
I-N-O
    	
 
    	
Brazil
    	
 
    	
5, 10,   42
    	
 
    	
818924136
    	
 
    	
12/11/1995
    	
 
    	
818924136
    	
 
    	
06/23/1998
    	
 
    	
 
    
	
INOBLENDER
    	
 
    	
Brazil
    	
 
    	
10
    	
 
    	
828287090
    	
 
    	
04/10/2006
    	
 
    	
828287090
    	
 
    	
05/06/2008
    	
 
    	
AGA   Aktiebolag
    
	
INOCAL
    	
 
    	
Brazil
    	
 
    	
1, 2,   3, 4, 5, 17, 21, 31, 35
    	
 
    	
819273074
    	
 
    	
07/01/1996
    	
 
    	
819273074
    	
 
    	
02/23/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Brazil
    	
 
    	
5, 10,   42
    	
 
    	
821749005
    	
 
    	
06/29/1999
    	
 
    	
821749005
    	
 
    	
01/27/2009
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Brazil
    	
 
    	
10
    	
 
    	
828279225
    	
 
    	
03/29/2006
    	
 
    	
828279225
    	
 
    	
05/06/2008
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Brazil
    	
 
    	
44
    	
 
    	
821729233
    	
 
    	
06/21/1999
    	
 
    	
821729233
    	
 
    	
03/11/2003
    	
 
    	
AGA   Aktiebolag
    
	
IKARIA
    	
 
    	
Canada
    	
 
    	
5, 10,   37, 42
    	
 
    	
1444140
    	
 
    	
07/08/2009
    	
 
    	
TMA787272
    	
 
    	
01/14/2011
    	
 
    	
Ikaria   Holdings Inc.
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
I-N-O
    	
 
    	
Canada
    	
 
    	
5
    	
 
    	
1086868
    	
 
    	
12/20/2000
    	
 
    	
TMA576774
    	
 
    	
03/03/2003
    	
 
    	
INO   Therapeutics LLC
    
	
INOblender
    	
 
    	
Canada
    	
 
    	
10
    	
 
    	
1296888
    	
 
    	
04/06/2006
    	
 
    	
TMA738591
    	
 
    	
04/22/2009
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Canada
    	
 
    	
5
    	
 
    	
1086867
    	
 
    	
12/20/2000
    	
 
    	
TMA576744
    	
 
    	
02/28/2003
    	
 
    	
INO Therapeutics   LLC
    
	
INOFLO
    	
 
    	
Canada
    	
 
    	
5
    	
 
    	
1018335
    	
 
    	
06/09/1999
    	
 
    	
TMA562856
    	
 
    	
05/30/2002
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Canada
    	
 
    	
5
    	
 
    	
1009727
    	
 
    	
03/24/1999
    	
 
    	
TMA621362
    	
 
    	
10/01/2004
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Canada
    	
 
    	
10
    	
 
    	
1294778
    	
 
    	
03/22/2006
    	
 
    	
TMA738008
    	
 
    	
04/15/2009
    	
 
    	
INO Therapeutics   LLC
    
	
INOPULSE
    	
 
    	
Canada
    	
 
    	
10
    	
 
    	
1110179
    	
 
    	
07/20/2001
    	
 
    	
TMA602882
    	
 
    	
02/20/2004
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Canada
    	
 
    	
5, 10,   37, 42
    	
 
    	
1018336
    	
 
    	
06/09/1999
    	
 
    	
TMA643009
    	
 
    	
06/27/2005
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Canada
    	
 
    	
10
    	
 
    	
817096
    	
 
    	
07/05/1996
    	
 
    	
TMA540612
    	
 
    	
01/31/2001
    	
 
    	
INO   Therapeutics LLC
    
	
ONSTORVIS
    	
 
    	
Canada
    	
 
    	
5
    	
 
    	
1622223
    	
 
    	
04/11/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
Ikaria   Therapeutics LLC
    
	
TERLIVAZ
    	
 
    	
Canada
    	
 
    	
5
    	
 
    	
1622222
    	
 
    	
04/11/2013
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
Ikaria   Therapeutics LLC
    
	
IKARIA
    	
 
    	
Chile
    	
 
    	
5, 10
    	
 
    	
855480
    	
 
    	
02/19/2009
    	
 
    	
875699
    	
 
    	
02/11/2010
    	
 
    	
Ikaria   Holdings Inc.
    
	
INOBLENDER
    	
 
    	
Chile
    	
 
    	
10
    	
 
    	
726119
    	
 
    	
04/11/2006
    	
 
    	
764847
    	
 
    	
08/14/2006
    	
 
    	
INO   Therapetics LLC
    
	
INOMAX
    	
 
    	
Chile
    	
 
    	
5
    	
 
    	
954234
    	
 
    	
05/24/2011
    	
 
    	
924725
    	
 
    	
06/27/2011
    	
 
    	
INO   Therapetics LLC
    
	
INOMAX
    	
 
    	
Chile
    	
 
    	
10
    	
 
    	
722926
    	
 
    	
03/14/2006
    	
 
    	
762143
    	
 
    	
07/10/2006
    	
 
    	
INO   Therapetics LLC
    
	
INOTHERAPY
    	
 
    	
Chile
    	
 
    	
5, 10
    	
 
    	
889954
    	
 
    	
12/29/2009
    	
 
    	
874937
    	
 
    	
11/22/2009
    	
 
    	
INO   Therapetics LLC
    
	
INOTHERAPY
    	
 
    	
Chile
    	
 
    	
41
    	
 
    	
889953
    	
 
    	
12/29/2009
    	
 
    	
874936
    	
 
    	
01/24/2010
    	
 
    	
INO   Therapetics LLC
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOVENT
    	
 
    	
Chile
    	
 
    	
10
    	
 
    	
754714
    	
 
    	
12/11/2006
    	
 
    	
784521
    	
 
    	
03/24/2007
    	
 
    	
INO   Therapetics LLC
    
	
INOBlender
    	
 
    	
China
    	
 
    	
9
    	
 
    	
G892785A
    	
 
    	
02/08/2006
    	
 
    	
G892785A
    	
 
    	
04/04/2006
    	
 
    	
AGA AB
    
	
INOBlender
    	
 
    	
China
    	
 
    	
10
    	
 
    	
G892785A
    	
 
    	
02/08/2006
    	
 
    	
G892785A
    	
 
    	
04/04/2006
    	
 
    	
AGA AB
    
	
INOBlender
    	
 
    	
China
    	
 
    	
11
    	
 
    	
G892785A
    	
 
    	
02/08/2006
    	
 
    	
G892785A
    	
 
    	
04/04/2006
    	
 
    	
AGA AB
    
	
INOMAX
    	
 
    	
China
    	
 
    	
10
    	
 
    	
G893015A
    	
 
    	
02/08/2006
    	
 
    	
G893015A
    	
 
    	
04/04/2006
    	
 
    	
AGA AB
    
	
INOMAX
    	
 
    	
China
    	
 
    	
11
    	
 
    	
G893015A
    	
 
    	
02/08/2006
    	
 
    	
G893015A
    	
 
    	
04/04/2006
    	
 
    	
AGA AB
    
	
INOMAX
    	
 
    	
China
    	
 
    	
42
    	
 
    	
G893015A
    	
 
    	
02/08/2006
    	
 
    	
G893015A
    	
 
    	
04/04/2006
    	
 
    	
AGA AB
    
	
INO
    	
 
    	
China
    	
 
    	
5
    	
 
    	
928660
    	
 
    	
03/29/1995
    	
 
    	
928660
    	
 
    	
01/14/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
China
    	
 
    	
5
    	
 
    	
928657
    	
 
    	
03/29/1995
    	
 
    	
928657
    	
 
    	
01/14/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
China
    	
 
    	
1
    	
 
    	
1464135
    	
 
    	
06/11/1999
    	
 
    	
1464135
    	
 
    	
10/28/2010
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
China
    	
 
    	
5
    	
 
    	
1507781
    	
 
    	
06/11/1999
    	
 
    	
1507781
    	
 
    	
01/14/2011
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
China
    	
 
    	
39
    	
 
    	
1467378
    	
 
    	
06/11/1999
    	
 
    	
1467378
    	
 
    	
10/28/2010
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
China
    	
 
    	
41
    	
 
    	
1459508
    	
 
    	
06/11/1999
    	
 
    	
1459508
    	
 
    	
10/14/2010
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
China
    	
 
    	
42
    	
 
    	
1459493
    	
 
    	
06/11/1999
    	
 
    	
1459493
    	
 
    	
10/14/2010
    	
 
    	
AGA   Aktiebolag
    
	
INOVENT
    	
 
    	
China
    	
 
    	
10
    	
 
    	
960071150
    	
 
    	
06/17/1996
    	
 
    	
1071982
    	
 
    	
08/07/1997
    	
 
    	
AGA   Aktiebolag
    
	
I-N-O
    	
 
    	
Colombia
    	
 
    	
5
    	
 
    	
02054901
    	
 
    	
06/25/2002
    	
 
    	
300687
    	
 
    	
08/04/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOCAL
    	
 
    	
Colombia
    	
 
    	
1
    	
 
    	
03092357
    	
 
    	
10/16/2003
    	
 
    	
302673
    	
 
    	
08/16/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOFLO
    	
 
    	
Colombia
    	
 
    	
5
    	
 
    	
99036215
    	
 
    	
06/09/1999
    	
 
    	
226864
    	
 
    	
05/19/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Colombia
    	
 
    	
5
    	
 
    	
99036226
    	
 
    	
06/09/1999
    	
 
    	
225942
    	
 
    	
04/13/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Colombia
    	
 
    	
39
    	
 
    	
99036219
    	
 
    	
06/09/1999
    	
 
    	
225945
    	
 
    	
04/13/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Colombia
    	
 
    	
41
    	
 
    	
99036218
    	
 
    	
06/09/1999
    	
 
    	
225946
    	
 
    	
04/13/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Colombia
    	
 
    	
42
    	
 
    	
99036217
    	
 
    	
06/09/1999
    	
 
    	
225943
    	
 
    	
04/13/2000
    	
 
    	
AGA   Aktiebolag
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOVENT
    	
 
    	
Colombia
    	
 
    	
10
    	
 
    	
96043125
    	
 
    	
08/14/1996
    	
 
    	
195231
    	
 
    	
03/19/1997
    	
 
    	
AGA   Aktiebolag
    
	
IKARIA
    	
 
    	
Community   Trademarks
    	
 
    	
5, 10,   42
    	
 
    	
004664652
    	
 
    	
10/21/2005
    	
 
    	
004664652
    	
 
    	
09/06/2006
    	
 
    	
Ikaria, Inc.
    
	

    	
 
    	
Community   Trademarks
    	
 
    	
5, 10,   42
    	
 
    	
005221593
    	
 
    	
07/26/2006
    	
 
    	
005221593
    	
 
    	
07/05/2007
    	
 
    	
Ikaria, Inc.
    
	
IKARIA
    	
 
    	
Community   Trademarks
    	
 
    	
9, 37,   44
    	
 
    	
007590722
    	
 
    	
02/10/2009
    	
 
    	
007590722
    	
 
    	
09/09/2009
    	
 
    	
Ikaria   Holdings Inc.
    
	
INO
    	
 
    	
Ecuador
    	
 
    	
5
    	
 
    	
63631
    	
 
    	
12/12/1995
    	
 
    	
2520
    	
 
    	
09/04/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOblender
    	
 
    	
Ecuador
    	
 
    	
10
    	
 
    	
169881
    	
 
    	
04/17/2006
    	
 
    	
2181-07
    	
 
    	
03/21/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Ecuador
    	
 
    	
1
    	
 
    	
69161
    	
 
    	
06/05/1996
    	
 
    	
4941
    	
 
    	
12/10/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Ecuador
    	
 
    	
10
    	
 
    	
168716
    	
 
    	
03/15/2006
    	
 
    	
1604-07
    	
 
    	
02/16/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Ecuador
    	
 
    	
10
    	
 
    	
69160
    	
 
    	
06/05/1996
    	
 
    	
4940-97
    	
 
    	
12/10/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOBLENDER
    	
 
    	
Hong   Kong
    	
 
    	
10
    	
 
    	
300619975
    	
 
    	
04/13/2006
    	
 
    	
300619975
    	
 
    	
09/14/2006
    	
 
    	
INO Therapeutics   LLC
    
	
INOCAL
    	
 
    	
Hong   Kong
    	
 
    	
1
    	
 
    	
199802985
    	
 
    	
06/11/1996
    	
 
    	
199802985
    	
 
    	
03/30/1998
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Hong   Kong
    	
 
    	
5
    	
 
    	
200003618
    	
 
    	
03/23/1999
    	
 
    	
200003618
    	
 
    	
02/29/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Hong   Kong
    	
 
    	
10
    	
 
    	
300601893
    	
 
    	
03/17/2006
    	
 
    	
300601893
    	
 
    	
08/10/2006
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
1
    	
 
    	
200004712
    	
 
    	
06/05/1999
    	
 
    	
200004712
    	
 
    	
03/23/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
5
    	
 
    	
200004713
    	
 
    	
06/05/1999
    	
 
    	
200004713
    	
 
    	
03/23/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
7
    	
 
    	
200101483
    	
 
    	
06/05/1999
    	
 
    	
200101483
    	
 
    	
02/09/2001
    	
 
    	
INO   Therapeutics LLC
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
10
    	
 
    	
200004714
    	
 
    	
06/05/1999
    	
 
    	
200004714
    	
 
    	
03/23/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
11
    	
 
    	
200101402
    	
 
    	
06/05/1999
    	
 
    	
200101402
    	
 
    	
02/08/2001
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
39
    	
 
    	
200105749
    	
 
    	
06/05/1999
    	
 
    	
200105749
    	
 
    	
05/17/2001
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
41
    	
 
    	
200106471
    	
 
    	
06/05/1999
    	
 
    	
200106471
    	
 
    	
06/01/2001
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Hong   Kong
    	
 
    	
42
    	
 
    	
200106472
    	
 
    	
06/05/1999
    	
 
    	
200106472
    	
 
    	
06/01/2001
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Hong   Kong
    	
 
    	
5
    	
 
    	
199702525
    	
 
    	
03/11/1995
    	
 
    	
199702525
    	
 
    	
03/07/1997
    	
 
    	
The BOC   Group Inc.
    
	
INOVENT
    	
 
    	
India
    	
 
    	
10
    	
 
    	
728393
    	
 
    	
06/24/1996
    	
 
    	
298112
    	
 
    	
06/24/1996
    	
 
    	
Ohmeda   Inc.
    
	
I-N-O
    	
 
    	
India
    	
 
    	
5
    	
 
    	
658085
    	
 
    	
03/09/1995
    	
 
    	
714394
    	
 
    	
03/28/2008
    	
 
    	
AGA   Aktiebolag
    
	
INOBLENDER
    	
 
    	
India
    	
 
    	
10
    	
 
    	
1447168
    	
 
    	
04/13/2006
    	
 
    	
748025
    	
 
    	
08/25/2008
    	
 
    	
AGA  Aktiebolag
    
	
INOCAL
    	
 
    	
India
    	
 
    	
1
    	
 
    	
728392
    	
 
    	
06/24/1996
    	
 
    	
267071
    	
 
    	
07/15/2003
    	
 
    	
The BOC   Group, Inc.
    
	
INOMAX
    	
 
    	
India
    	
 
    	
5
    	
 
    	
658089
    	
 
    	
03/09/1995
    	
 
    	
285498
    	
 
    	
01/06/2004
    	
 
    	
Ohmeda   Inc.
    
	
INOMAX
    	
 
    	
India
    	
 
    	
10
    	
 
    	
1433164
    	
 
    	
03/15/2006
    	
 
    	
748006
    	
 
    	
08/25/2008
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
India
    	
 
    	
7
    	
 
    	
860253
    	
 
    	
06/09/1999
    	
 
    	
265158
    	
 
    	
06/13/2003
    	
 
    	
AGA   Aktiebolag
    
	
IKARIA
    	
 
    	
Indonesia
    	
 
    	
5, 10
    	
 
    	
D002009006782
    	
 
    	
03/03/2009
    	
 
    	
IDM000271544
    	
 
    	
09/21/2010
    	
 
    	
Ikaria   Holdings Inc.
    
	
INOREG
    	
 
    	
Indonesia
    	
 
    	
11
    	
 
    	
R002008007428
    	
 
    	
07/15/2009
    	
 
    	
IDM000213550
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
INOREG
    	
 
    	
Indonesia
    	
 
    	
11
    	
 
    	
R002008008669
    	
 
    	
10/14/2009
    	
 
    	
IDM000234196
    	
 
    	
01/25/2010
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
1
    	
 
    	
R002008007436
    	
 
    	
07/15/2009
    	
 
    	
IDM000213557
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
5
    	
 
    	
R002008007429
    	
 
    	
07/15/2009
    	
 
    	
IDM000213551
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
10
    	
 
    	
R002008007432
    	
 
    	
07/15/2009
    	
 
    	
IDM000213553
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
11
    	
 
    	
R002008007431
    	
 
    	
07/15/2009
    	
 
    	
IDM000213552
    	
 
    	
08/13/2009
    	
 
    	
 
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
11
    	
 
    	
R002008008672
    	
 
    	
10/14/2009
    	
 
    	
IDM000234197
    	
 
    	
01/25/2010
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
39
    	
 
    	
V002008007435
    	
 
    	
07/15/2009
    	
 
    	
IDM000213556
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
41
    	
 
    	
V002008007433
    	
 
    	
07/15/2009
    	
 
    	
IDM000213554
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
INOTHERAPY
    	
 
    	
Indonesia
    	
 
    	
44
    	
 
    	
V002008007434
    	
 
    	
07/15/2009
    	
 
    	
IDM000213555
    	
 
    	
08/13/2009
    	
 
    	
 
    
	
I-N-O
    	
 
    	
Indonesia
    	
 
    	
5
    	
 
    	
R00200500549
    	
 
    	
03/22/20005
    	
 
    	
IDM000238514
    	
 
    	
03/02/2010
    	
 
    	
 
    
	
INOMAX
    	
 
    	
Indonesia
    	
 
    	
5
    	
 
    	
R00200500550
    	
 
    	
03/22/2005
    	
 
    	
IDM000238515
    	
 
    	
03/02/2010
    	
 
    	
 
    
	
IKARIA
    	
 
    	
Japan
    	
 
    	
5, 9,   10, 37, 42, 44
    	
 
    	
2009-052455
    	
 
    	
07/10/2009
    	
 
    	
5312137
    	
 
    	
03/26/2010
    	
 
    	
Ikaria   Holdings Inc.
    
	
アイノキャル (INOCAL in Katakana)
    	
 
    	
Japan
    	
 
    	
1
    	
 
    	
2003-037253
    	
 
    	
05/08/2003
    	
 
    	
4768539
    	
 
    	
04/30/2004
    	
 
    	
INO   Therapeutics LLC
    
	
INOFLO
    	
 
    	
Japan
    	
 
    	
1, 5
    	
 
    	
H11-051919
    	
 
    	
06/11/1999
    	
 
    	
4455017
    	
 
    	
02/23/2001
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Japan
    	
 
    	
5
    	
 
    	
H11-025043
    	
 
    	
03/19/1999
    	
 
    	
4359499
    	
 
    	
02/04/2000
    	
 
    	
INO   Therapeutics LLC
    
	
アイノマックス (INOMAX in Katakana)
    	
 
    	
Japan
    	
 
    	
5
    	
 
    	
2003-037251
    	
 
    	
05/08/2003
    	
 
    	
4783465
    	
 
    	
07/02/2004
    	
 
    	
INO   Therapeutics LLC
    
	
INOMETER
    	
 
    	
Japan
    	
 
    	
9, 10,   42, 44
    	
 
    	
2002-083154
    	
 
    	
10/01/2002
    	
 
    	
4710141
    	
 
    	
09/12/2003
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Japan
    	
 
    	
5, 10,   41, 42
    	
 
    	
H11-058119
    	
 
    	
06/28/1999
    	
 
    	
4478969
    	
 
    	
06/01/2001
    	
 
    	
INO   Therapeutics LLC
    
	
アイノセラピー (INOTHERAPY in Katakana)
    	
 
    	
Japan
    	
 
    	
5, 10,   44
    	
 
    	
2003-037252
    	
 
    	
05/08/2003
    	
 
    	
4765385
    	
 
    	
04/16/2004
    	
 
    	
INO   Therapeutics LLC
    
	
イノベント (INOVENT in Katakana)
    	
 
    	
Japan
    	
 
    	
10
    	
 
    	
2001-045864
    	
 
    	
05/22/2001
    	
 
    	
4628986
    	
 
    	
12/13/2002
    	
 
    	
INO   Therapeutics LLC
    
	
INOPULSE
    	
 
    	
Japan
    	
 
    	
10
    	
 
    	
2012-52253
    	
 
    	
06/28/2012
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
INO   Therapeutics LLC
    
	
I-N-O
    	
 
    	
Malaysia
    	
 
    	
5
    	
 
    	
95003799
    	
 
    	
04/24/1995
    	
 
    	
95003799
    	
 
    	
04/24/1995
    	
 
    	
AGA   Aktiebolag
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOblender
    	
 
    	
Malaysia
    	
 
    	
10
    	
 
    	
06006346
    	
 
    	
04/19/2006
    	
 
    	
06006346
    	
 
    	
04/19/2006
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Malaysia
    	
 
    	
1
    	
 
    	
97010861
    	
 
    	
08/06/1997
    	
 
    	
97010861
    	
 
    	
08/06/1997
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Malaysia
    	
 
    	
5
    	
 
    	
95003803
    	
 
    	
04/24/1995
    	
 
    	
95003803
    	
 
    	
04/24/1995
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Malaysia
    	
 
    	
10
    	
 
    	
06004524
    	
 
    	
03/22/2006
    	
 
    	
06004524
    	
 
    	
03/22/2006
    	
 
    	
AGA   Aktiebolag
    
	
INOREG
    	
 
    	
Malaysia
    	
 
    	
7
    	
 
    	
99005103
    	
 
    	
06/14/1999
    	
 
    	
99005103
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOREG
    	
 
    	
Malaysia
    	
 
    	
11
    	
 
    	
99005106
    	
 
    	
06/14/1999
    	
 
    	
99005106
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
1
    	
 
    	
99005108
    	
 
    	
06/14/1999
    	
 
    	
99005108
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
5
    	
 
    	
99005109
    	
 
    	
06/14/1999
    	
 
    	
99005109
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
7
    	
 
    	
99005248
    	
 
    	
06/16/1999
    	
 
    	
99005248
    	
 
    	
06/16/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
10
    	
 
    	
99005105
    	
 
    	
06/14/1999
    	
 
    	
99005105
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
11
    	
 
    	
99005113
    	
 
    	
06/14/1999
    	
 
    	
99005113
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
39
    	
 
    	
99005112
    	
 
    	
06/14/1999
    	
 
    	
99005112
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
41
    	
 
    	
99005111
    	
 
    	
06/14/1999
    	
 
    	
99005111
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Malaysia
    	
 
    	
44
    	
 
    	
99005110
    	
 
    	
06/14/1999
    	
 
    	
99005110
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOVENT
    	
 
    	
Malaysia
    	
 
    	
10
    	
 
    	
97010799
    	
 
    	
08/05/1997
    	
 
    	
97010799
    	
 
    	
08/05/1997
    	
 
    	
Datex-Ohmeda   Inc.
    
	
INOFLO
    	
 
    	
Malaysia
    	
 
    	
1
    	
 
    	
99005107
    	
 
    	
06/14/1999
    	
 
    	
99005107
    	
 
    	
06/14/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOBLENDER
    	
 
    	
Mexico
    	
 
    	
10
    	
 
    	
777519
    	
 
    	
04/17/2006
    	
 
    	
932936
    	
 
    	
04/28/2006
    	
 
    	
AGA   Aktiebolag
    
	
INOCAL
    	
 
    	
Mexico
    	
 
    	
1
    	
 
    	
795525
    	
 
    	
07/21/2006
    	
 
    	
980431
    	
 
    	
04/19/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Mexico
    	
 
    	
5
    	
 
    	
368830
    	
 
    	
03/24/1999
    	
 
    	
660113
    	
 
    	
06/26/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Mexico
    	
 
    	
10
    	
 
    	
771663
    	
 
    	
03/14/2006
    	
 
    	
929989
    	
 
    	
04/21/2006
    	
 
    	
AGA   Aktiebolag
    
	
INOMETER
    	
 
    	
Mexico
    	
 
    	
9
    	
 
    	
636290
    	
 
    	
01/07/2004
    	
 
    	
824044
    	
 
    	
02/27/2004
    	
 
    	
AGA   Aktiebolag
    
	
INOMETER
    	
 
    	
Mexico
    	
 
    	
10
    	
 
    	
636289
    	
 
    	
01/07/2004
    	
 
    	
824496
    	
 
    	
03/09/2004
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
1
    	
 
    	
380022
    	
 
    	
06/22/1999
    	
 
    	
622110
    	
 
    	
08/31/1999
    	
 
    	
AGA   Aktiebolag
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
5
    	
 
    	
380026
    	
 
    	
06/22/1999
    	
 
    	
620493
    	
 
    	
08/30/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
10
    	
 
    	
380021
    	
 
    	
06/22/1999
    	
 
    	
622109
    	
 
    	
08/31/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
11
    	
 
    	
380017
    	
 
    	
06/22/1999
    	
 
    	
622106
    	
 
    	
08/31/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
11
    	
 
    	
380020
    	
 
    	
06/22/1999
    	
 
    	
624904
    	
 
    	
09/27/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
39
    	
 
    	
380025
    	
 
    	
06/22/1999
    	
 
    	
647546
    	
 
    	
03/28/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
41
    	
 
    	
380016
    	
 
    	
06/22/1999
    	
 
    	
656311
    	
 
    	
05/30/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Mexico
    	
 
    	
42
    	
 
    	
380018
    	
 
    	
06/22/1999
    	
 
    	
622107
    	
 
    	
08/31/1999
    	
 
    	
AGA   Aktiebolag
    
	
INOVENT
    	
 
    	
Mexico
    	
 
    	
10
    	
 
    	
795890
    	
 
    	
07/24/2006
    	
 
    	
969641
    	
 
    	
01/25/2007
    	
 
    	
Datex-Ohmeda   Inc.
    
	
IKARIA
    	
 
    	
New   Zealand
    	
 
    	
5, 10,   37, 42, 44
    	
 
    	
802093
    	
 
    	
02/04/1999
    	
 
    	
802093
    	
 
    	
08/12/2010
    	
 
    	
Ikaria   Holdings Inc.
    
	
I-N-O
    	
 
    	
New   Zealand
    	
 
    	
5
    	
 
    	
244337
    	
 
    	
12/22/1994
    	
 
    	
244337
    	
 
    	
01/24/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOblender
    	
 
    	
New   Zealand
    	
 
    	
10
    	
 
    	
746071
    	
 
    	
04/07/2006
    	
 
    	
746071
    	
 
    	
07/12/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
New   Zealand
    	
 
    	
1
    	
 
    	
263005
    	
 
    	
06/04/1996
    	
 
    	
263005
    	
 
    	
07/21/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
New   Zealand
    	
 
    	
10
    	
 
    	
744310
    	
 
    	
03/10/2006
    	
 
    	
744310
    	
 
    	
09/14/2006
    	
 
    	
INO   Therapeutics LLC
    
	
INOREG
    	
 
    	
New   Zealand
    	
 
    	
7
    	
 
    	
310701
    	
 
    	
06/04/1999
    	
 
    	
310701
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOREG
    	
 
    	
New   Zealand
    	
 
    	
11
    	
 
    	
310700
    	
 
    	
06/04/1999
    	
 
    	
310700
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
1
    	
 
    	
310704
    	
 
    	
06/04/1999
    	
 
    	
310704
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
5
    	
 
    	
310705
    	
 
    	
06/04/1999
    	
 
    	
310705
    	
 
    	
12/07/2000
    	
 
    	
INO Therapeutics   LLC
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
7
    	
 
    	
310706
    	
 
    	
06/04/1999
    	
 
    	
310706
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
10
    	
 
    	
310707
    	
 
    	
06/04/1999
    	
 
    	
310707
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
11
    	
 
    	
310708
    	
 
    	
06/04/1999
    	
 
    	
310708
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
39
    	
 
    	
310709
    	
 
    	
06/04/1999
    	
 
    	
310709
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
New Zealand
    	
 
    	
41
    	
 
    	
310710
    	
 
    	
06/04/1999
    	
 
    	
310710
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
New   Zealand
    	
 
    	
42
    	
 
    	
310711
    	
 
    	
06/04/1999
    	
 
    	
310711
    	
 
    	
12/07/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
New   Zealand
    	
 
    	
10
    	
 
    	
263006
    	
 
    	
06/04/1996
    	
 
    	
263006
    	
 
    	
09/11/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOblender
    	
 
    	
Pakistan
    	
 
    	
10
    	
 
    	
220555
    	
 
    	
04/07/2006
    	
 
    	
220555
    	
 
    	
11/01/2010
    	
 
    	
AGA   Aktiebolag
    
	
INOCAL
    	
 
    	
Pakistan
    	
 
    	
1
    	
 
    	
167271
    	
 
    	
10/24/2000
    	
 
    	
167271
    	
 
    	
10/24/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOFLO
    	
 
    	
Pakistan
    	
 
    	
1
    	
 
    	
155649
    	
 
    	
06/10/1999
    	
 
    	
155649
    	
 
    	
Unknown
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Pakistan
    	
 
    	
10
    	
 
    	
219440
    	
 
    	
03/10/2006
    	
 
    	
219440
    	
 
    	
05/25/2011
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Pakistan
    	
 
    	
1
    	
 
    	
155648
    	
 
    	
06/10/1999
    	
 
    	
155648
    	
 
    	
10/11/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Pakistan
    	
 
    	
11
    	
 
    	
155656
    	
 
    	
06/10/1999
    	
 
    	
155656
    	
 
    	
12/08/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Pakistan
    	
 
    	
5
    	
 
    	
153912
    	
 
    	
Unknown
    	
 
    	
153912
    	
 
    	
Unknown
    	
 
    	
AGA   Aktiebolag
    
	
I-N-O
    	
 
    	
Pakistan
    	
 
    	
5
    	
 
    	
167274
    	
 
    	
10/24/2000
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
AGA   Aktiebolag
    
	
INOFLO
    	
 
    	
Pakistan
    	
 
    	
5
    	
 
    	
155650
    	
 
    	
06/10/1999
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Pakistan
    	
 
    	
16
    	
 
    	
155909
    	
 
    	
06/25/1999
    	
 
    	
Not Applicable
    	
 
    	
Not   Applicable
    	
 
    	
AGA   Aktiebolag
    
	
I-N-O
    	
 
    	
Philippines
    	
 
    	
5
    	
 
    	
41995099402
    	
 
    	
03/31/1995
    	
 
    	
41995099402
    	
 
    	
07/30/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOblender
    	
 
    	
Philippines
    	
 
    	
10
    	
 
    	
42006003882
    	
 
    	
04/07/2006
    	
 
    	
42006003882
    	
 
    	
03/05/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOCAL
    	
 
    	
Philippines
    	
 
    	
1
    	
 
    	
42004007800
    	
 
    	
08/24/2004
    	
 
    	
42004007800
    	
 
    	
12/24/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOFLO
    	
 
    	
Philippines
    	
 
    	
1, 5
    	
 
    	
42002007546
    	
 
    	
09/05/2002
    	
 
    	
42002007546
    	
 
    	
05/09/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Philippines
    	
 
    	
5
    	
 
    	
42006003069
    	
 
    	
03/17/2006
    	
 
    	
42006003069
    	
 
    	
11/13/2006
    	
 
    	
AGA   Aktiebolag
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOREG
    	
 
    	
Philippines
    	
 
    	
7, 11
    	
 
    	
42002007548
    	
 
    	
09/05/2002
    	
 
    	
42002007548
    	
 
    	
03/20/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Philippines
    	
 
    	
1, 5,   7, 10, 11, 39, 41, 42
    	
 
    	
42002007547
    	
 
    	
09/05/2002
    	
 
    	
42002007547
    	
 
    	
03/20/2005
    	
 
    	
AGA   Aktiebolag
    
	
INOMAX
    	
 
    	
Philippines
    	
 
    	
5
    	
 
    	
42009500140
    	
 
    	
3/26/2009
    	
 
    	
42009500140
    	
 
    	
8/13/2009
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Philippines
    	
 
    	
10
    	
 
    	
42006002837
    	
 
    	
3/13/2006
    	
 
    	
42006002837
    	
 
    	
4/30/2007
    	
 
    	
AGA   Aktiebolag
    
	
IKARIA
    	
 
    	
Singapore
    	
 
    	
5, 9,   10, 37, 42, 44
    	
 
    	
T09014281
    	
 
    	
02/12/2009
    	
 
    	
T09014281
    	
 
    	
05/21/2009
    	
 
    	
Ikaria   Holdings Inc.
    
	
INOCAL
    	
 
    	
Singapore
    	
 
    	
1
    	
 
    	
T9605650C
    	
 
    	
06/05/1996
    	
 
    	
T9605650C
    	
 
    	
11/29/1999
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Singapore
    	
 
    	
5
    	
 
    	
T9902879I
    	
 
    	
03/23/1999
    	
 
    	
T9902879I
    	
 
    	
09/14/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Singapore
    	
 
    	
5
    	
 
    	
T9906031E
    	
 
    	
06/14/1999
    	
 
    	
T9906031E
    	
 
    	
09/22/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Singapore
    	
 
    	
10
    	
 
    	
T9906033A
    	
 
    	
06/14/1999
    	
 
    	
T9906033A
    	
 
    	
11/01/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Singapore
    	
 
    	
10
    	
 
    	
T9605651A
    	
 
    	
06/05/1996
    	
 
    	
T9605651A
    	
 
    	
06/01/1999
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Singapore
    	
 
    	
11
    	
 
    	
T0525595H
    	
 
    	
12/20/2005
    	
 
    	
T0525595H
    	
 
    	
01/23/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOVENT
    	
 
    	
South   Africa
    	
 
    	
10
    	
 
    	
1996/07268
    	
 
    	
06/03/1996
    	
 
    	
1996/07268
    	
 
    	
09/01/1999
    	
 
    	
 
    
	
INOBLENDER
    	
 
    	
South   Africa
    	
 
    	
10
    	
 
    	
2006/07894
    	
 
    	
04/07/2006
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
 
    
	
IKARIA
    	
 
    	
Taiwan
    	
 
    	
5, 10
    	
 
    	
098004085
    	
 
    	
02/06/2009
    	
 
    	
01411355
    	
 
    	
05/16/2010
    	
 
    	
Akaria   Holdings Inc.
    
	
INOblender
    	
 
    	
Taiwan
    	
 
    	
10
    	
 
    	
095017730
    	
 
    	
04/10/2006
    	
 
    	
01248877
    	
 
    	
02/01/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Taiwan
    	
 
    	
1
    	
 
    	
85026895
    	
 
    	
06/03/1996
    	
 
    	
00766655
    	
 
    	
07/16/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Taiwan
    	
 
    	
5
    	
 
    	
84009974
    	
 
    	
03/07/1995
    	
 
    	
00713867
    	
 
    	
04/16/1996
    	
 
    	
INO   Therapeutics LLC
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOMAX
    	
 
    	
Taiwan
    	
 
    	
10
    	
 
    	
95011908
    	
 
    	
03/13/1996
    	
 
    	
01234266
    	
 
    	
11/01/1996
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Taiwan
    	
 
    	
1
    	
 
    	
88029585
    	
 
    	
06/16/1999
    	
 
    	
00910823
    	
 
    	
11/01/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Taiwan
    	
 
    	
5
    	
 
    	
88029584
    	
 
    	
06/16/1999
    	
 
    	
00908744
    	
 
    	
10/16/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Taiwan
    	
 
    	
10
    	
 
    	
88029582
    	
 
    	
06/16/1999
    	
 
    	
00890901
    	
 
    	
05/01/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Taiwan
    	
 
    	
11
    	
 
    	
88029581
    	
 
    	
06/16/1999
    	
 
    	
00907828
    	
 
    	
10/01/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Taiwan
    	
 
    	
41
    	
 
    	
88029579
    	
 
    	
06/16/1999
    	
 
    	
00131154
    	
 
    	
10/16/2000
    	
 
    	
INO Therapeutics   LLC
    
	
INOTHERAPY
    	
 
    	
Taiwan
    	
 
    	
42
    	
 
    	
88029578
    	
 
    	
06/16/1999
    	
 
    	
00137557
    	
 
    	
02/01/2001
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Taiwan
    	
 
    	
5
    	
 
    	
84009979
    	
 
    	
03/07/1995
    	
 
    	
713868
    	
 
    	
04/16/1996
    	
 
    	
INO   Therapeutics LLC
    
	
INOTHERAPY
    	
 
    	
Thailand
    	
 
    	
5
    	
 
    	
392056
    	
 
    	
07/08/1999
    	
 
    	
TM121076
    	
 
    	
07/08/1999
    	
 
    	
AGA AB
    
	
INOTHERAPY
    	
 
    	
Thailand
    	
 
    	
10
    	
 
    	
392058
    	
 
    	
07/08/1999
    	
 
    	
TM124636
    	
 
    	
07/08/1999
    	
 
    	
AGA AB
    
	
INOVENT
    	
 
    	
Thailand
    	
 
    	
10
    	
 
    	
312549
    	
 
    	
07/11/1996
    	
 
    	
TM60264
    	
 
    	
08/15/1996
    	
 
    	
AGA AB
    
	
INOblender
    	
 
    	
Thailand
    	
 
    	
10
    	
 
    	
623525
    	
 
    	
04/12/2006
    	
 
    	
TM251215
    	
 
    	
04/12/2006
    	
 
    	
AGA AB
    
	
INOMAX
    	
 
    	
Thailand
    	
 
    	
10
    	
 
    	
621585
    	
 
    	
03/24/2006
    	
 
    	
TM254899
    	
 
    	
03/24/2006
    	
 
    	
AGA AB
    
	
IKARIA
    	
 
    	
Uruguay
    	
 
    	
5, 10
    	
 
    	
399805
    	
 
    	
02/17/2009
    	
 
    	
399805
    	
 
    	
01/17/2012
    	
 
    	
Akaria   Holdings Inc.
    
	
I-N-O
    	
 
    	
Uruguay
    	
 
    	
5
    	
 
    	
381551
    	
 
    	
06/08/2007
    	
 
    	
381551
    	
 
    	
08/04/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOblender
    	
 
    	
Uruguay
    	
 
    	
10
    	
 
    	
370252
    	
 
    	
04/20/2006
    	
 
    	
370252
    	
 
    	
05/16/2007
    	
 
    	
INO   Therapeutics LLC
    
	
INOCAL
    	
 
    	
Uruguay
    	
 
    	
1
    	
 
    	
392509
    	
 
    	
05/30/2008
    	
 
    	
392509
    	
 
    	
06/05/1998
    	
 
    	
INO   Therapeutics LLC
    
	
INOMAX
    	
 
    	
Uruguay
    	
 
    	
5
    	
 
    	
429525
    	
 
    	
11/18/2011
    	
 
    	
Not   Applicable
    	
 
    	
11/26/2001
    	
 
    	
AGA   Aktiebolag
    

 

 

	
Mark
    	
 
    	
Country
    	
 
    	
Class(es)
    	
 
    	
Application
   No.
    	
 
    	
Application
   Date
    	
 
    	
Registration
   No.
    	
 
    	
Registered
    	
 
    	
Registered
   Owner
    
	
INOMAX
    	
 
    	
Uruguay
    	
 
    	
10
    	
 
    	
369364
    	
 
    	
03/10/2006
    	
 
    	
369364
    	
 
    	
03/28/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Uruguay
    	
 
    	
5, 10,   11, 39, 41, 44
    	
 
    	
419863
    	
 
    	
01/27/2011
    	
 
    	
419863
    	
 
    	
08/01/2000
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Uruguay
    	
 
    	
10
    	
 
    	
287645
    	
 
    	
06/13/1996
    	
 
    	
287645
    	
 
    	
08/04/1997
    	
 
    	
INO   Therapeutics LLC
    
	
INOVENT
    	
 
    	
Venezuela
    	
 
    	
10
    	
 
    	
2011-001901
    	
 
    	
02/07/2011
    	
 
    	
Not   Applicable
    	
 
    	
Not   Applicable
    	
 
    	
INO   Therapeutics LLC
    
	
I-N-O
    	
 
    	
Venezuela
    	
 
    	
5
    	
 
    	
1995-020086
    	
 
    	
12/12/1995
    	
 
    	
P197278
    	
 
    	
05/09/1997
    	
 
    	
AGA Aktiebolag
    
	

    	
 
    	
Venezuela
    	
 
    	
10
    	
 
    	
2006-007649
    	
 
    	
04/07/2006
    	
 
    	
P282088
    	
 
    	
10/24/2007
    	
 
    	
AGA   Aktiebolag
    
	
INOCAL
    	
 
    	
Venezuela
    	
 
    	
1
    	
 
    	
1996-008395
    	
 
    	
06/06/1996
    	
 
    	
P202514
    	
 
    	
01/23/1998
    	
 
    	
The BOC   Group, Inc.
    
	
INOMAX
    	
 
    	
Venezuela
    	
 
    	
10
    	
 
    	
2006-005678
    	
 
    	
06/17/2006
    	
 
    	
P275561
    	
 
    	
11/30/2006
    	
 
    	
AGA Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Venezuela
    	
 
    	
10
    	
 
    	
1999-010553
    	
 
    	
06/17/1999
    	
 
    	
P222135
    	
 
    	
07/07/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Venezuela
    	
 
    	
39
    	
 
    	
1999-010546
    	
 
    	
06/17/1999
    	
 
    	
S013332
    	
 
    	
07/07/2000
    	
 
    	
AGA   Aktiebolag
    
	
INOTHERAPY
    	
 
    	
Venezuela
    	
 
    	
41
    	
 
    	
1999-010545
    	
 
    	
06/17/1999
    	
 
    	
S013331
    	
 
    	
07/07/2000
    	
 
    	
AGA   Aktiebolag
    

 

 

Schedule 1.1(b)

 

R&DCo Intellectual Property

 

	
IKARIA
   REFERENCE
   NUMBER
    	
 
    	
TITLE
    	
 
    	
COUNTRY
    	
 
    	
STATUS
    	
 
    	
FILING DATE
    	
 
    	
APPLICATION
   NUMBER
    
	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    
	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    
	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    
	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    

 

 

Schedule 6.1(c)

 

Indemnification Matters

 

The R&DCo Option Payments

 

 

Schedule 8.13(a)

 

R&DCo Assets Used in or Necessary for Ikaria Business

 

None.

 

 

Schedule 8.13(b)

 

Required Consents

 

None.

 

 

Exhibit A

 

Form of Device Clinical Supply Agreement

 

Incorporated by reference to Exhibit 10.11 to the Company’s Registration Statement on Form S-1

 

 

Exhibit B

 

Form of Drug Clinical Supply Agreement

 

Incorporated by reference to Exhibit 10.12 to the Company’s Registration Statement on Form S-1

 

 

Exhibit C

 

Form of Employee Matters Agreement

 

Incorporated by reference to Exhibit 10.13 to the Company’s Registration Statement on Form S-1

 

 

Exhibit D

 

Form of R&D Cross License Agreement

 

Incorporated by reference to Exhibit 10.14 to the Company’s Registration Statement on Form S-1

 

 

Exhibit E

 

Form of Transition Services Agreement

 

Incorporated by reference to Exhibit 10.15 to the Company’s Registration Statement on Form S-1Exhibit 10.11

 

Execution Version

 

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.

 

DEVICE CLINICAL SUPPLY AGREEMENT

 

This Device Clinical Supply Agreement (this “Agreement”) is entered into as of February 9, 2014 (the “Effective Date”) by and between by and between INO Therapeutics LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (“Ikaria”), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (“Pulse Technologies”).  Ikaria and Pulse Technologies may be individually referred to as a “Party” and together as the “Parties.”

 

WHEREAS, the Parties were formerly owned by a common parent company, Ikaria, Inc. (“Ikaria Parent Company”);

 

WHEREAS, Pulse Technologies has, as part of certain spin-out transactions (the “Spin-Out”), ceased to be a direct or indirect subsidiary of Ikaria Parent Company, and is now therefore not owned by, or affiliated with, either Ikaria Parent Company or Ikaria;

 

WHEREAS, Pulse Technologies is engaged in the business of developing, manufacturing, and commercializing products for (a) pulmonary hypertension secondary to chronic obstructive pulmonary disease (“COPD”) and (b) primary or idiopathic pulmonary arterial hypertension (“PAH”) (collectively, the “Pulse Technologies Clinical Programs”);

 

WHEREAS, prior to the Spin-Out, Ikaria manufactured the nitric oxide delivery devices listed in Exhibit A to this Agreement (the “Devices”) used by Pulse Technologies as part of the Pulse Technologies Clinical Programs; and

 

WHEREAS, Pulse Technologies wishes Ikaria to continue on a short term basis to manufacture, and Ikaria wishes to continue to manufacture, the Devices for Pulse Technologies, all subject to and in accordance with the terms and conditions of this Agreement.

 

NOW THEREFORE, in consideration of the foregoing premises, which are incorporated into and made a part of this Agreement, and of the mutual covenants which are recited herein, the Parties agree as follows:

 

1.                                      Definitions.

 

1.1          “Affiliate” means, with respect to a Party, any Person directly or indirectly controlling, controlled by or under common control with, such Party.  For purposes of this definition only, “control” of a Person shall mean the ability, directly or indirectly, to direct the activities of the relevant Person, and with respect to corporate entities shall mean (a) ownership or direct control of fifty percent (50%) or more of the outstanding voting stock or other ownership interest of such Person, or (b) direct or indirect possession, of the power to elect or appoint fifty percent (50%) or more of the members of the governing body of such Person.  Notwithstanding the foregoing or any direct or indirect control relationship that exists between them, Ikaria and Pulse Technologies shall be deemed not to be Affiliates of one another.

 

1.2          “COGS” means, as to Ikaria and its Affiliates, with respect to the Devices, the aggregate of internal and external costs of Ikaria and its Affiliates to manufacture such Devices, calculated as follows: (a) to the extent that Ikaria or its Affiliates performs all or any part of the manufacturing of such Devices, the actual direct material costs and direct labor costs for, plus manufacturing overhead reasonably allocable to, such manufacturing of such Devices (which may include the costs of audits, all directly incurred manufacturing variances,  manufacturing administrative and facilities costs (including

 

1

 

depreciation)), all calculated in accordance with GAAP; and (b) to the extent that manufacturing of such Devices is performed by a Third Party, the costs paid to such Third Party for such activities  and the reasonably allocated direct labor costs incurred by Ikaria or any of its Affiliates in managing and overseeing the Third Party relationship, determined in accordance with GAAP.

 

1.3          “Confidential Information” means information disclosed by a Party or its Affiliate (such Party referred to as the “Disclosing Party”) to the other Party or its Affiliate (such Party referred to as the “Receiving Party”), which information relates either directly or indirectly to the business of the Disclosing Party, including information and data regarding the manufacture or use, pre-clinical or clinical data regarding, the status of research or development of any Device.  Confidential Information of the Disclosing Party excludes any information that the Receiving Party can establish by written records: (a) was known by the Receiving Party prior to receipt from the Disclosing Party; (b) was disclosed to the Receiving Party by a Third Party having the right to do so; (c) was, or subsequently became, publicly known through no fault of the Receiving Party or its Affiliates; or (d) was concurrently or subsequently developed by personnel of the Receiving Party without having had access to the Disclosing Party’s Confidential Information.

 

1.4          “COPD” shall have the meaning set forth in the recitals to this Agreement.

 

1.5          “Cross License” shall mean the Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement by and between the Parties dated of even date herewith.

 

1.6          “Devices” shall have the meaning set forth in the recitals to this Agreement.

 

1.7          “Device IP” shall have the meaning set forth in Section 2.9.

 

1.8          “Effective Date” shall have meaning set forth in the preamble to this Agreement.

 

1.9          “Facility” means Ikaria’s manufacturing facilities located in Madison, WI, or such other manufacturing site(s) specified by Ikaria from time to time.

 

1.10        “FDA” means the United States Food and Drug Administration or any successor organization.

 

1.11        “Federal Health Care Programs” shall have the meaning set forth in Section 5.4.

 

1.12        “Forecast” shall have the meaning set forth in Section 2.5.

 

1.13        “Ikaria Parent Company” shall have the meaning set forth in the recitals to this Agreement.

 

1.14        “Intellectual Property” means, collectively, patents, trademarks, copyrights (including to any software, whether in object code or source code form), trade secrets, know-how, and any other intellectual or proprietary property or rights.

 

1.15        “PAH” shall have the meaning set forth in the recitals to this Agreement.

 

1.16        “Person” means any individual, governmental authority, partnership, corporation, limited liability company, unincorporated organization or association, any trust or any other business entity.

 

1.17        “Pulse Technologies Clinical Programs” shall have the meaning set forth in the recitals to

 

2

 

this Agreement.

 

1.18        “Purchase Order” means a written purchase order issues by Pulse Technologies to Ikaria for the purchase of Devices.

 

1.19        “Quality Agreement” has the meaning set forth in Section 3.

 

1.20        “Regulatory Authority” means any competent governmental authority which regulates the manufacture, development or sale of any Device.

 

1.21        “Specification” means, with respect to each Device, the specifications in effect at Ikaria for that Device immediately prior to the Spin-Out.

 

1.22        “Term” has the meaning set forth in Section 8.1.

 

1.23        “Third Party” means any Person who is not a Party or an Affiliate of a Party.

 

2.                                      Supply of Devices.

 

2.1          Obligations of Ikaria.  During the Term of this Agreement, Ikaria will use commercially reasonable efforts to manufacture and supply Pulse Technologies’ requirements for Devices for the Pulse Technologies Clinical Programs in accordance with the terms of this Agreement and the Quality Agreement.  Pulse Technologies acknowledges and agrees that nothing in this Agreement shall require Ikaria to hire, obtain, or retain additional resources of any type (whether personnel, infrastructure, or otherwise), or to make capital expenditures of any kind, in order to manufacture and supply the Devices, nor shall anything in this Agreement require Ikaria to prioritize manufacturing and supplying the Devices to Pulse Technologies over performing similar services for its own benefit.

 

2.2          Obligations of Pulse Technologies.  Pulse Technologies will provide Ikaria with such information and cooperation as may be necessary for the manufacture and supply of the Devices in accordance with this Agreement and the Quality Agreement.

 

2.3          Changes.  Ikaria shall use commercial reasonable efforts to accommodate any reasonable changes to the Specifications for the Devices, it being understood and agreed that Pulse Technologies shall bear any and all costs associated with such changes.  Pulse Technologies further acknowledges and agrees that no such requested change may be inconsistent with, or violative of, the terms and conditions of the Cross License, including the restricted abilities, attributes, capabilities, capacities, functions, and specifications set forth in Exhibit A to the Cross License.

 

2.4          Pricing.  Pricing for the Devices shall be as set forth in Exhibit B to this Agreement, and shall be subject to the other terms and conditions set forth therein.

 

2.5          Forecasts.  Within 10 business days after the Effective Date, Pulse Technologies shall provide to Ikaria a written forecast of all Devices which Pulse Technologies expects to order from Ikaria during the Term (the “Forecast”).  Pulse Technologies shall update the Forecast in writing on a monthly basis.  The Forecast shall constitute a non-binding, good faith estimate provided by Pulse Technologies solely to assist Ikaria in production planning, and shall not represent any purchase commitment by Pulse Technologies or a supply commitment by Ikaria.

 

2.6          Purchase Orders.

 

3

 

(a)           During the Term, Pulse Technologies may place Purchase Orders with Ikaria.  Acknowledging that the lead time for the Devices is estimated to be between four and six months, Pulse Technologies agrees to submit all Purchase Orders no later than six months after the Effective Date.  Each Purchase Order shall specify the specific Devices ordered.  Ikaria shall be deemed to have accepted a Purchase Order unless it objects within 30 days after receiving such Purchase Order.  If Ikaria’s believes it will be unable to manufacture the requested Devices (e.g., because of an inability to obtain required component parts), Ikaria shall promptly inform Pulse Technologies thereof.  If a Purchase Order is accepted by, or deemed accepted by Ikaria under this Section 2.6(a), then Ikaria shall use commercially reasonable efforts to produce the quantity of Devices set forth in the Purchase Order.

 

(b)           Each Purchase Order and any acknowledgment thereof shall be governed by the terms of this Agreement.  If a Party uses forms or documents to place or accept Purchase Order that contain terms and conditions that are in addition to or contrary to those in this Agreement, the Parties agree and acknowledge that such forms or documents will be used for convenience only, and that no terms or conditions set forth therein, except with respect to quantity, shall be of any force or effect.

 

2.7          Delivery.  Ikaria shall deliver the Devices to a carrier selected by Pulse Technologies.  The Devices shall be made available EXW the Facility (Incoterms 2010).  Title and risk of loss will pass to Pulse Technologies when the Devices are made available to the carrier selected by Pulse Technologies.  Pulse Technologies is responsible for payment of all shipment costs, including any insurance necessary to guard against loss or damage during shipment.

 

2.8          Inspection and Acceptance of Devices.

 

(a)           Pulse Technologies shall have 30 days from the date of receipt of each Device to inspect and reject acceptance by written notice to Ikaria; provided, however, that any such notice shall set forth Pulse Technologies’ reasons for rejection in reasonable detail and provided, further, that Pulse Technologies may reject a Device only if Pulse Technologies believes that the Device in question does not conform in all material respects with the applicable Specifications.  If Ikaria does not receive Pulse Technologies’ written notice of rejection within such 30 day period, Pulse Technologies shall be deemed to have accepted such Device.

 

(b)           If Pulse Technologies provides Ikaria with a timely notice of rejection under Section 2.8(a), Pulse Technologies shall return the rejected Device(s) to Ikaria at Ikaria’s expense.  Ikaria shall have 30 days following receipt of the rejected Devices in which to test such Devices.  If Ikaria does not dispute a rejection, Ikaria shall rework or replace the rejected Device(s), at Ikaria’s expense and such rework or replacement shall constitute Pulse Technologies’ exclusive remedy and Ikaria’s sole liability with respect to such rejection.  If Ikaria disputes a rejection, Ikaria shall provide Pulse Technologies with written notice of such dispute within 30 days after receiving the returned Devices, and the Parties shall use commercially reasonable efforts to resolve the dispute amicably and promptly.  If the Parties are unable to reach a resolution within 30 days after Pulse Technologies’ notice of rejection, the returned Devices shall be submitted to an independent consultant mutually acceptable to the Parties, whose decision as to the conformity of such Devices with the applicable Specification shall be final and binding.  The Party against whom the dispute is decided shall pay any charges for such consultant.  If the consultant determines that the returned Devices did not conform to the Specification, Ikaria shall rework or replace the rejected Devices at no charge to Pulse Technologies, and such replacement shall constitute Pulse Technologies’ exclusive remedy and Ikaria’s sole liability with respect to such rejected Devices.

 

2.9          No Licenses.  Pulse Technologies acknowledges and agrees that nothing in this Agreement grants, or shall be deemed or interpreted to grant, to Pulse Technologies any right, title, or interest in or to any Intellectual Property reflected, contained, or incorporated in, or practice under, as part

 

4

 

of or in the process of manufacturing and delivery of Devices (collectively, the “Device IP”).  Pulse Technologies acknowledges and agrees that it is obtaining ownership to the physical Devices only under this Agreement, and not to or in any of the Device IP.

 

3.             Quality Agreement.  The Parties shall use reasonable efforts to negotiate and conclude a quality agreement (“Quality Agreement”) within 60 days after the Effective Date.  The Quality Agreement shall detail the division of responsibilities between the Parties regarding quality and regulatory controls and reporting concerning the Devices.  In the case of a conflict between the Quality Agreement and this Agreement, the terms of this Agreement shall control unless such term in the Quality Agreement expressly references such conflict and the Parties intend to have the Quality Agreement control such provision.

 

4.             Audit Rights.  Pulse Technologies shall have the right to conduct reasonable audits and inspections of the Facility, Ikaria’s manufacturing operations, and Ikaria’s records relating to the manufacture of Devices under this Agreement.  Ikaria shall reasonably cooperate with Pulse Technologies in conducting such audits and inspections.

 

5.                                      Warranties.

 

5.1          General Warranties.  Each Party warrants to the other Party that (a) it has the right and authority to enter into this Agreement and to carry out its obligations hereunder; (b) it is validly existing in the jurisdiction in which it is incorporated and is authorized to do business under the laws of each jurisdiction in which it engages in business activities; and (c) it is not aware of any legal, contractual or other restriction, limitation or condition that might adversely affect its ability to perform its obligations hereunder.

 

5.2          Warranties by Ikaria.  Ikaria warrants to Pulse Technologies that each Device delivered hereunder shall conform in all material respects with its applicable Specifications.  Pulse Technologies agrees that its exclusive remedies, and Ikaria’s sole liabilities, with respect to any breach of the warranty set forth in this Section 5.2 are set forth in Section 2.8 of this Agreement.

 

5.3          Pass Through Warranties.  Ikaria shall use commercially reasonable efforts to pass-through to Pulse Technologies the benefit of any warranties on component parts incorporated into the Devices to the extent Ikaria has the right to do so.  Pulse Technologies acknowledges and agrees that this Section 5.3 does not provide Pulse Technologies with any additional rights or remedies vis-à-vis Ikaria beyond those stated in Section 5.

 

5.4          Debarment.  Each party represents and warrants that, as of the Effective Date and throughout the Term, it (and each of its employees and agents) (a) is not currently excluded, debarred or otherwise ineligible to participate in the Federal health care programs as defined in 42 U.S.C. 1320a7b(f) (the “Federal Health Care Programs”); (b) has not been convicted of a criminal offense related to the provision of healthcare items or services but yet to be excluded, debarred or otherwise declared ineligible to participate in the Federal Health Care Programs; and (c) is not under investigation or otherwise aware of any circumstances which may result in it (or its agents, employees or any substitutes thereof performing any duties under this Agreement) being excluded from participation in the Federal Health Care Programs.

 

5.5          DISCLAIMER.  EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES NOR RECEIVES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, OR ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE PRACTICE, WITH REGARD TO THE DEVICES OR OTHERWISE UNDER

 

5

 

THIS AGREEMENT, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE.

 

6.             Indemnity.  Pulse Technologies shall indemnify, defend and hold Ikaria, its Affiliates and their respective directors, officers, employees, agents, successors and assigns harmless from and against any damages, losses, judgments, claims, suits, actions, liabilities, costs and expenses (including, but not limited to, reasonable attorneys’ fees), as and when incurred, resulting from any Third Party claims or suits arising out of the ownership, use, handling, development, distribution, marketing, or sale of any Device.

 

7.                                      Compliance.

 

7.1          Compliance with Laws.  Each Party shall comply with all applicable laws and regulations governing the performance of such Party’s obligations under this Agreement.  Without limiting the foregoing, each Party shall comply with applicable US and other laws, rules and regulations that govern the import, export and re-export of the  Devices, including the U.S. Export Administration Regulations, and will obtain any required export and import authorizations to perform its obligation hereunder.

 

7.2          Regulatory Filings.  Pulse Technologies, at its expense, shall be solely responsible for the preparation, filing, and maintenance of all regulatory documents and all governmental permits, licenses and other approvals as may be necessary with respect to the formulation, marketing, distribution, sale, and use of each Device.

 

7.3          Permits.  Ikaria at its expense shall be solely responsible for, and has the obligation to prepare, file, and maintain during the Term, all licenses, permits, and approvals as may be necessary with respect to the manufacture of Devices at the Facility.

 

8.                                      Term and Termination.

 

8.1          Term.  Unless otherwise terminated under this Section 8, this Agreement will commence as of the Effective Date and will continue for a period of twelve months (the “Term”); provided, however, that if a Purchase Order that has been accepted by Ikaria has not been fulfilled at the expiration of the Term, this Agreement shall continue to remain in effect for so long as necessary to complete the delivery of Devices under that Purchase Order.

 

8.2          Termination.  This Agreement may be terminated by either Party upon 60 days written notice of the other Party’s material breach of any provision of this Agreement; provided, however, that the breaching Party will have an opportunity to (a) cure the breach during the 60 day notice period, or (b) provide the non-breaching Party with a plan to remedy the breach within the 60 day notice period, and if so cured, no termination will be deemed to have occurred as long as the breaching Party diligently pursues the plan to remedy the breach and completes such plan in accordance with the time frame agreed to by the Parties (such time frame not to exceed an additional 60 days).

 

8.3          Effect of Termination.  Termination or expiration of this Agreement shall not release either Party from any liability, right of action or other obligation which has arisen prior to such termination or expiration, including Ikaria’s obligation to deliver to Pulse Technologies such quantity of Devices under any accepted Purchase Order to the effective date of termination or expiration, and Pulse Technologies’ obligation to pay Ikaria the amount set forth in such Purchase Order.  Notwithstanding any expiration or termination of this Agreement, the following provisions shall survive:  Sections 2.6(b), 2.8(b), 2.9, 5.5, 6, 8.3, 9, 10, and 11, as well as Pulse Technologies’ payment obligations under Exhibit B.

 

6

 

9.                                      Confidentiality.

 

9.1          Non-Use and Non-Disclosure of Confidential Information.  Each Receiving Party agrees that all Confidential Information of the Disclosing Party (a) shall not be used by the Receiving Party except to perform its obligations or exercise its rights under this Agreement, (b) shall be maintained in confidence by the Receiving Party, and (c) except as permitted by Section 9.2, shall not be disclosed by the Receiving Party to any Person without the prior written consent of the Disclosing Party.

 

9.2          Permitted Disclosures.

 

(a)           The Receiving Party may provide the Disclosing Party’s Confidential Information (i) to its Affiliates and to their employees, consultants, advisors, and contractors who have a need to know such Confidential Information for purposes of the Receiving Party exercising or granting licenses or sublicenses, (ii) in communications with existing or bona fide prospective acquirers, merger partners, lenders or investors, in each case of (i) and (ii), on a need to know basis and under appropriate confidentiality provisions substantially equivalent to those of this Agreement.

 

(b)           The Receiving Party may provide the Disclosing Party’s Confidential Information:

 

(i)            to the Receiving Party’s employees, consultants, advisors and contractors who have a need to know such Confidential Information and are bound by an obligation to maintain the confidentiality of the Disclosing Party’s Confidential Information;

 

(ii)           to patent offices or regulatory authorities in order to seek or obtain patent rights or approval to conduct clinical trials, or to gain regulatory approvals;

 

(iii)          as reasonably required for development of Devices, in accordance with normal and customary commercial practice; or

 

(iv)          if such disclosure is required by law (including by rules or regulations of any securities exchange) or to defend or prosecute litigation or arbitration; provided, that prior to such disclosure, to the extent permitted by law or such rules or regulations, the Receiving Party promptly notifies the Disclosing Party of such requirement and furnishes only that portion of the Disclosing Party’s Confidential Information that the Receiving Party is legally required to furnish.

 

10.                               Limitations of Liability.

 

10.1        EXCEPT IN CONNECTION WITH PULSE TECHNOLOGIES’ INDEMNIFICATION OBLIGATIONS UNDER SECTION 6, IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES, BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS, LOST DATA, OR LOSS OF USE) ARISING OUT OF THIS AGREEMENT, REGARDLESS OF WHETHER SUCH DAMAGES ARE BASED ON TORT, WARRANTY, CONTRACT OR ANY OTHER LEGAL THEORY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  THIS EXCLUSION IS INDEPENDENT OF ANY OTHER REMEDY SET FORTH IN THIS AGREEMENT.

 

10.2        TO THE FULLEST EXTENT PERMITTED BY LAW, IKARIA’S LIABILITY TO PULSE TECHNOLOGIES UNDER THIS AGREEMENT IS LIMITED TO THE AGGREGATE AMOUNTS PAID OR PAYABLE BY PULSE TECHNOLOGIES TO IKARIA IN RESPECT OF THE RELEVANT PURCHASE ORDER FROM WHICH THE CLAIM AROSE.

 

7

 

11.                               Miscellaneous.

 

11.1        Notices.  All notices required or permitted to be given under this Agreement must be in writing and delivered to the other Party as set forth below.  Notices are validly given upon the earlier of confirmed receipt by the receiving Party or three business days after dispatch by a reputable courier or certified mail, return receipt requested.  Either Party may change its designated contact and address for purposes of notice by giving notice to the other Party in accordance with these provisions.

 

If to Ikaria:

 

INO Therapeutics LLC

Perryville III Corporate Park

53 Frontage Road, Third Floor

P. O. Box 9001

Hampton, NJ 08827

Attention:  General Counsel

 

If to Pulse Technologies:

 

Bellerophon Pulse Technologies LLC

Perryville III Corporate Park

53 Frontage Road, Third Floor

P. O. Box 9001

Hampton, NJ 08827

Attention:  General Counsel

 

11.2        Escalated Dispute Resolution.  Prior to pursuing legal remedies hereunder, the Parties’ relationship managers agree to negotiate in good faith to resolve any disputes arising during performance of this Agreement.  If such negotiations and meetings do not resolve the dispute within 10 business days after notice of the dispute, then a senior executive from each Party will meet within 10 days or as agreed between them to attempt to resolve such dispute.  If the dispute is not resolved to the satisfaction of these executives within 10 days, then either Party may pursue all available legal remedies.  Notwithstanding the foregoing, either Party may seek injunctive relief with respect to any disputed matter without following the dispute resolution procedure set forth above.

 

11.3        Force Majeure.  Neither Party will be liable for any failure or delay in performance of its obligations under this Agreement to the extent such failure or delay is caused by any event beyond such Party’s reasonable control, which may include fire, flood, explosion, unavailability of utilities or raw materials, labor difficulties, war, riot, act of God, export control regulation, or other laws or regulations, action or failure to act of any governmental authority, or any judgment, injunction or order of a court, administrative agency or regulatory authority having the effect of preventing or adversely affecting either Party’s performance under this Agreement.

 

11.4        Independent Contractors.  The relationship of the Parties established under this Agreement is that of independent contractors and neither Party is a partner, employee, agent or joint venturer of or with the other.

 

11.5        Assignment.   Except as otherwise provided in this Section 11.5, neither this Agreement nor any part hereof may be assigned or transferred by either Party, whether by operation of law or otherwise, without the other Party’s prior written consent.  Notwithstanding the foregoing, either Party

 

8

 

may assign this Agreement, without the other Party’s prior consent, in the event of a sale or transfer of the business as to which this Agreement relates, whether such sale or transfer occurs by merger, reorganization, asset and/or stock purchase, or by any other means, provided that the assignee agrees in writing to assume all of the assignor’s obligations under this Agreement.  Any assignment or purported assignment in violation hereof shall be void.  This Agreement will be binding upon and inure to the benefit of the Parties and their permitted successors and assigns.

 

11.6        Headings; Construction; Interpretation.  Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement.  The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise.  Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement.  Any reference in this Agreement to an Article, Section, subsection, paragraph, clause or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause or Exhibit, of or to, as the case may be, this Agreement.  Except where the context otherwise requires, (a) any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein); (b) any reference to any law refers to such law as from time to time enacted, repealed or amended; (c) the words “herein,” “hereof” and “hereunder,” and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; (d) the words “include,” “includes,” “including,” “exclude,” “excludes,” and “excluding,” shall be deemed to be followed by the phrase “but not limited to,” “without limitation” or words of similar import; and (e) all references in this Agreement to “days” will, unless otherwise specified herein, mean calendar days.

 

11.7        No Third Party Beneficiaries.  No provisions of this Agreement are intended to confer or give, or will be construed to confer or give, to any person or entity other than Ikaria and Pulse Technologies any rights, remedies or other benefits under or by reason of this Agreement.

 

11.8        Severability.  If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid or unenforceable in any respect, such determination will not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each provision is hereby declared to be separate, severable and distinct.  To the extent that any such provision is found to be invalid, illegal or unenforceable, the Parties will negotiate in good faith to substitute for such provision, to the extent possible, a new provision that most nearly effects the Parties’ original intent in entering into this Agreement or to provide an equitable adjustment in the event no such provision can be added.  The other provisions of this Agreement will remain in full force and effect.

 

11.9        Entire Agreement.  This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior communications, representations or agreements, whether oral or written.  No modifications, amendments, or waiver of any term, condition or provision of this Agreement will be binding on either Party unless in writing and signed by an authorized representative of each Party.

 

11.10      Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey, USA, without giving effect to any conflict of law provisions.

 

9

 

11.11      Counterparts.  This Agreement may be executed in counterparts each of which, when executed and delivered, shall be original, but all such counterparts shall constitute one and the same document.  The Parties agree that signatures transmitted via portable document format (PDF) shall be deemed originals until originals replace such copies.

 

10

 

IN WITNESS WHEREOF, each of the Parties has caused this Device Clinical Supply Agreement to be executed on its behalf by a duly authorized officer on the date first set forth above.

 

 

	
INO THERAPEUTICS LLC   d/b/a IKARIA
    	
 
    	
BELLEROPHON PULSE
   TECHNOLOGIES LLC
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Matthew M. Bennett
    	
 
    	
By:
    	
/s/ Daniel Tassé
    
	
 
    	
 
    	
 
    
	
Name: Matthew M. Bennett
    	
 
    	
Name: Daniel Tassé
    
	
 
    	
 
    	
 
    
	
Title: Vice   President & Secretary
    	
 
    	
Title: Chief Executive Officer
    
					

 

 

EXHIBIT A

DEVICES

 

INOpulse DS for PAH

 

INOpulse DS-C for COPD

 

INOpulse Mark 1

 

CCM (Clinical Control Module)

 

 

EXHIBIT B

PRICING

 

Pricing for the Devices shall be as follows:

 

	
Device
    	
 
    	
Pricing
    
	
 
    	
 
    	
 
    
	
INOpulse   DS for PAH
    	
 
    	
COGS   plus [**]%
    
	
 
    	
 
    	
 
    
	
INOpulse   DS-C for COPD
    	
 
    	
COGS   plus [**]%
    
	
 
    	
 
    	
 
    
	
INOpulse   Mark 1
    	
 
    	
COGS   plus [**]%
    
	
 
    	
 
    	
 
    
	
CCM   (Clinical Control Module)
    	
 
    	
COGS   plus [**]%
    

 

Ikaria shall invoice Pulse Technologies as follows in respect of each Purchase Order accepted by Ikaria hereunder:

 

(a)                                 promptly following acceptance of a Purchase Order by Ikaria, Ikaria shall invoice Pulse Technologies for estimated COGS for the Devices covered by the applicable Purchase Order; and

 

(b)                                 upon completion of the Devices (i.e., the Devices are available for pickup by Pulse Technologies EXW Ikaria’s Facilities as described in Section 2.7 of the Agreement), Ikaria shall invoice Pulse Technologies for (i) any actual COGS in excess of estimated COGS (or if actual COGS is less than estimated COGS, then Ikaria shall grant a credit in the appropriate amount), and (ii) the additional percentage fee specified in this Exhibit B.

 

Pulse Technologies shall promptly pay each invoice hereunder (but in all events, within 30 days after each such invoice has been issued by Ikaria), it being acknowledged and agreed by Pulse Technologies that (a) Ikaria shall not be required to take any further action with respect to the Devices under a Purchase Order unless and until Pulse Technologies has paid the applicable invoice in full, and (b) Ikaria shall not be required to release any Devices for pick-up until the applicable invoice has been paid in full.

 

All amounts not paid when due shall bear interest from the due date at the rate of the lesser of (a) [**] percent ([**]%) per month or (b) the maximum amount permitted by applicable law.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]